{
  "name" : "twin.sci-hub.se_6337_acb530711e6a28e84622927d18876150_anderson2017.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Protease-Sensitive Nanomaterials for Cancer Therapeutics and Imaging",
    "authors" : [ "Caleb F Anderson", "Honggang Cui", "Caleb F. Anderson" ],
    "emails" : [ "hcui6@jhu.edu," ],
    "sections" : [ {
      "heading" : null,
      "text" : "1\nMany diseases can be characterized by the abnormal activity exhibited by various\nbiomolecules, the targeting of which can provide therapeutic and diagnostic utility. Recent trends\nin medicine and nanotechnology have prompted the development of protease-sensitive\nnanomaterials systems for therapeutic, diagnostic, and theranostic applications. These systems\ncan act specifically in response to the target enzyme and its associated disease conditions, thus\nenabling personalized treatment and improved prognosis. In this review, we discuss recent\nadvancements in the development of protease-responsive materials for imaging and drug\ndelivery and analyze several representative systems to illustrate their key design principles.\nACS Paragon Plus Environment\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n2"
    }, {
      "heading" : "Introduction",
      "text" : "Enzymatic proteins can exhibit abnormal activity in a wide variety of diseases such as\ncancer and autoimmune disorders and, therefore, can be exploited for therapeutic and diagnostic\npurposes.1–5 This anomalous activity can help to increase the specificity and selectivity of drugs\nto diseased sites to reduce the harmful consequences of impacting healthy tissues and cells. The\nability to precisely detect these activities could also prove beneficial for early stage diagnosis and\nenable a more accurate evaluation of disease progression. Moreover, imaging of these\nbiomolecules can provide real time information in an noninvasive manner, thus allowing the\nselection of the most appropriate medical treatments.6\nEnzymes play crucial roles in the progression and spread of cancer, being involved in the\nprocesses of cancer cell growth, angiogenesis, and metastasis among others. This importance\nmakes enzymes suitable targets for therapeutic and diagnostic purposes.1,7–9 There are many\nunique aspects of tumor physiology and pathology that can be utilized for targeting and\ntreatment. For example, many tumor types contain leaky, irregularly shaped blood vessels that\nallow therapeutics and imaging probes to easily enter the tumor; poor lymphatic drainage then\nleads to greater retention.10 For greater selectivity, however, an active targeting strategy is\npreferred, one that provides a distinct means of distinguishing cancerous tissues from healthy. In\nthis case, targeting of abnormally expressed enzymes could be advantageous, though there are\nalso other tumor microenvironment factors that can be targeted for improved selectivity,\nincluding pH,11,12 cell-surface receptors,13,14 redox potential,15 hypoxia,16 and more.17,18\nEnzymes are relevant and effective targets for selective cancer drug and imaging probe\ndelivery due to their substrate specificity and ability to perform biological catalysis.4,19,20 A wide\nvariety of enzyme classes are overexpressed in tumor microenvironments, such as proteases,\nlipases, oxidoreductases, and phosphatases, and serve as potential targets;3,21 however, our focus\nPage 2 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n3\nhere will center on cancer-associated proteases. The proteases that can be used for cancer therapy\nand imaging are cathepsins,22,23 matrix metalloproteinases,24,25 caspases,9 and urokinases.7,19,26\nWith a specific protease in mind, responsive drugs and imaging probes can be designed for that\ntarget to increase selectivity and efficacy.\nNanomaterials have been used for various medicinal applications and have made a\nsignificant impact on the field of drug delivery and diagnosis by improving efficacy and reducing\nsystemic toxicity.4,27 A wide variety of platform nanostructures and materials have been\ndeveloped,3,28 including liposomes,29 dendrimers,30 inorganic nanoparticles,31–33 hydrogels,34–36\nprotein conjugates,37 and polymeric nanoparticles.38–40 Several key design features impact their\npharmacokinetic profiles and biodistribution, such as shape, size, and surface chemistry, and\nmust be considered when developing new nanomedicines.41–46 Specifically, in cancer imaging\nand treatment, nanomaterial-based systems offer many advantages over small molecule drugs\nand imaging probes. Nanomaterials have greater solubility and stability in vivo with longer\ncirculation times and slower clearance rates that allow for sustained delivery. With their ability\nto be engineered for particular stimuli-responsiveness, enhanced accumulation in tumors, and\nhigh loading capacity from high surface-area-to-volume ratios, nanomaterials serve as ideal\ncandidates for combating cancer.4,47 Certain nanomaterials can also be formed from self-\nassembling monomers, offering further advantages by simplifying formulation and development\nthrough the reduction of unnecessary components.44,47 Nanomaterials can be designed to interact\nwith enzymes to induce self-assembly or to trigger drug release within the confines of the\ntumor(s), which can improve targeting efficacy and reduce unwanted signals or side-effects in\nhealthy tissues.48–50\nPage 3 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n4\nSome nanomaterials have found utility in medicine as imaging probes activatable by\nproteases, whereby enzymatic cleavage turns the probes “on” to yield a detectable signal.6,51,52\nThis concept is illustrated in Figure 1. Protease-activated materials have been applied to a wide\nvariety of imaging techniques for disease detection, such as optical/fluorescence imaging,\nmagnetic resonance imaging (MRI), nuclear imaging (PET, SPECT, and CT), and more.49,53–55\nRecent efforts have pushed for the development of imaging probes with multiple modalities to\nbenefit from the advantages each component offers for more accurate signaling.56 Using\nprotease-sensitive nanomaterials for molecular imaging can improve overall accuracy by\nenhancing target-site accumulation, increasing detectable signals via enzymatic cleavage,\nimproving resistance to nonspecific degradation, and accelerating clearance from the body to\nreduce background noise. For cancer, these nanomaterial-based probes can present precise\ninformation for early detection, staging, diagnosis, and response monitoring to improve patient\ncare.55\nThe benefits of using protease-responsive nanomaterials for imaging directly translate to\nefficacious drug delivery,1 which is also illustrated in Figure 1. In recent years, trends in\nnanomedicine have been for the development of theranostic agents that are capable of\nsimultaneous or tandem diagnosis and therapy.27,28,57 The combination of imaging and\ntherapeutic capabilities in a nanomaterial-based delivery system offers advantages over imaging\nand therapeutics alone, with minor trade-offs that can be mitigated by incorporating protease-\nsensitivity into its design. Theranostic probes can reveal when and how drugs are delivered and\nallow for monitoring of a patient’s response to therapy. From the information obtained by\ndirectly visualizing the pharmacokinetics of these agents, it can assist healthcare providers in\ndecision-making by revealing optimal therapeutic strategies for that specific patient, paving the\nPage 4 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n5\nway toward personalized medicine in the future. Using nanomaterial-based systems as\ntheranostic agents will improve therapeutic efficacy, mitigate off-target toxicity, and ultimately\nlead to better patient outcomes. Integrating protease-sensitivity improves selective accumulation\nand activation at diseased sites and can help overcome the trade-offs between the different\ntimescales needed for imaging and therapeutics. Molecules with intrinsic duality are ideal\ncandidates, as they are simpler to synthesize and do not have to compromise on the extent of\nloading between the imaging agent and the drug.57–62\nIn this review, we will discuss recent advances in imaging and drug delivery with\nprotease-responsive nanomaterials for cancer with a focus on theranostic systems, paying\nparticular attention to their molecular design. Since there has been a conscious effort in\nnanomedicine to design systems sensitive to multiple environmental stimuli for improved\nselectivity and signal ratios,13,16,63 our discussion will also include systems that incorporate\nresponsiveness to other tumor microenvironment factors in conjunction with protease sensitivity.\nPage 5 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n6\nFigure 1. Tissues containing healthy (pink) and tumor (grey) cells can be treated with various nanomaterials, such as (from left to right) liposomes, protein-conjugates, polymeric nanoparticles, hydrogels, dendrimers, and inorganic metal nanoparticles, to deliver imaging agents or anticancer drugs with improved selectivity to tumor cells by incorporation of protease-responsiveness into the design of nanomaterials.\nProtease-responsive nanomaterial systems for therapeutics Nanomaterials have been widely employed for the improvement of already commercially\navailable anticancer therapeutics, where their ability to improve drug solubility and retention in\ntumors has helped increase efficacy and safety.16,33,40,41,44,64,65 Incorporation of protease\nsensitivity can further improve selectivity to tumor tissue and mitigate harmful side effects to\nhealthy tissues.66–69 Of particular interest are the following proteases whose abnormal activity is\nassociated with cancer: cathepsins, matrix metalloproteinases, and urokinase-type plasminogen\nactivators. Cathepsins are lysosomal cysteine proteases that play a role in regulating\nangiogenesis during cancer progression and in initiating and promoting tumor formation, growth,\ninvasion, and metastasis.22,23 Matrix metalloproteinases (MMPs) are extracellular zinc-containing\nPage 6 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n7\nextracellular matrix (ECM) endopeptidases that play a role in tumor growth, invasion, and\nmetastasis.24 The urokinase-type plasminogen activator (uPA) is a serine protease and a member\nof the uPA system on the cell surface; uPA degrades the ECM and activates its substrate\nplasmin, which is more destructive. Its activity plays a role in enhancing cell migration, invasion,\nand metastasis.70 While proteases are most often utilized to release drugs from nanomaterial\ncarriers, recent studies have been investigated using proteases for inducing formation of\nnanostructures that may be cytotoxic to cancer cells themselves or to change the shape or size of\nnanocarriers to impact drug release profiles.21 In this section, we will discuss recent studies on\nthe design of protease-responsive nanomaterials that release drug cargo or aggregate in tumor\nmicroenvironments to yield therapeutic effects, including some examples of systems responsive\nto other additional microenvironment factors."
    }, {
      "heading" : "Protease-responsiveness for cargo release",
      "text" : "In one example, Bossmann and coworkers worked to develop a protease-sensitive\nliposome that would address common problems faced by liposome carriers, such as decreasing\nthe amount of leaking from the vesicles, increasing their release kinetics, and being able to target\ncancer cells more specifically.71 The liposomes were designed with a cholesterol-anchored, graft\ncopolymer containing a uPA-cleavable peptide sequence (SGRSA) and polyacrylic acid, and the\nliposomes used have high osmolarities to make them swell more easily. The liposomes are\ncrosslinked with diamine and ethylenediamine, which causes the liposomes to exhibit\nsignificantly increased resistance to osmotic swelling and thus prevents premature leaking of\ntheir contents. In the presence of uPA, these liposomes are able to deliver their entire payload,\nindicating their heightened sensitivity to the protease. The focus of this study was on creating\nand optimizing the design of these liposomes, so no in vitro or in vivo studies were conducted.\nPage 7 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n8\nAn optimal design was created by looking at the impact of crosslinking level and degree of\npolymer-incorporation on release against osmotic pressure, showcasing the numerous factors and\nimportance of nanomaterial design to be efficacious for drug delivery.71\nIn another example, He and coworkers developed a mesoporous silica nanoparticle\n(MSN) to improve the targeting of the anticancer drug doxorubicin (Dox) to cancer cells while\nreducing adverse side effects to healthy cells.72 MSNs are suitable drug carriers because they\nhave a large loading capacity, are easily functionalized, have low toxicity, and are chemically\ninert. This design involves a classic rotaxane structure formed between an alkoxysilane tether\nand alpha-cyclodextrin (α-CD) used to anchor onto orifices of MSNs and act as gatekeeper for\ndoxorubicin release. These are modified with a multifunctional peptide (azido-GFLGR7RGDS)\nthat contains αvβ3 integrin (overexpressed on the surfaces of different cancer lines) targeting\nsequence RGDS, cell penetrating peptide sequence R7, and cathepsin B-cleavable peptide\nsequence GFLG, which function to selectively penetrate tumor cells and release doxorubicin.\nFigure 2 showcases the design of these MSNs and their mechanism of action. Drug release\nbehavior studies with nanoparticles in PBS showed that the nanoparticles had the greatest release\nof contents in the presence of cathepsin B at lysosomal pH, indicating the requirement of\ncathepsin B cleavage for sufficient drug delivery. In vitro studies were conducted with αvβ3-\npositive HeLa cancer cells that overexpress cathepsin B and αvβ3-negative COS7 cells that\nexpress cathepsin B at relatively low levels. These studies showed higher uptake in HeLa cells\nbut lower cytotoxicity than free doxorubicin, as seen in Figure 2, by flow cytometry and MTT\nassay. The difference in cytotoxicity between the MSNs and free Dox is likely due to the slower\nrate of endocytosis of the MSNs as opposed to concentration gradient diffusion by free Dox;\nhowever, the MSNs have an increased selectivity from αvβ3-targeting and cathepsin B-triggered\nPage 8 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n9\ndrug release that makes them safer alternatives to the free drug. The difference in cell viability\nbetween HeLa cells, αvβ3 receptor-blocked HeLa cells, and COS7 cells highlights the selectivity\nof the αvβ3- and cathepsin B-targeting motifs of the MSNs. While no in vivo study has been\nconducted with these MSNs, this study highlights the advantages of targeting other tumor\nmicroenvironment factors (specifically receptor overexpression) in conjunction with protease\noverexpression for improving the selectivity of drug delivery and release to cancer cells over\nhealthy cells.72\nFigure 2. (A-F) The functionalization procedure and mechanism of action of the doxorubicin-loaded mesoporous silica nanoparticles (MSNs), where (A) shows capping of and subsequent release from the MSNs of doxorubicin, (B) shows the drug-loaded MSNs as they appear in physiological pH, (C) illustrates targeting to αVβ3 integrins overexpressed on cancer cells by the RGDS peptide sequence, (D) portrays endocytosis of MSNs into a specific tumor cells, (E) shows triggered drug release by cathepsin B activity, and (F) represents the tumor cell undergoing apoptosis. (G) Cell viability data of COS7 and HeLa cells incubated in vitro with doxorubicin-loaded MSNGFLGR7RGDS/α-CD in the absence or presence of free RGDS peptide (2 µM) and (H) free doxorubicin, highlighting the comparable cytotoxicity as the free drug but with more specificity to tumor cells. Adapted with permission from reference 72. Copyright 2015 American Chemical Society.\nIn another example with multi-responsiveness, Jiang and coworkers developed a\nnanoparticle system responsive to both extracellular pH and MMP-2 activity for gene delivery.73\nPage 9 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n10\nTheir design involves dendrigraft poly-lysine (DGL) that complexes and condenses DNA to\nform a non-viral vector nanoparticle via electrostatic interactions. The nanoparticles are modified\nwith a dual-triggered activatable cell-penetrating peptide (dtACPP), composed of a pH-sensitive\nmasking peptide (e4k4, D-amino acids, pI = 6.4), an MMP-2 substrate (PLGLAG), and a\npolycationic cell-penetrating peptide (nonarginine). The dtACPPs are conjugated to the surface\nof a DGL via α-Malemidyl-ω-N-hydroxysuccinimidyl polyethylene glycol (MAL-PEG-NHS) to\ncreate the gene nanocarrier, dtACPP-PEG-DGL (dtACPPD). The internalization of the\nnanoparticles via the cell-penetrating peptide is inhibited until the nanoparticles enter\nenvironments with pH values typical of tumors; here the now positively or neutrally-charged pH-\nsensitive masking peptide can be cleaved by overexpressed MMP-2 to then enhance cellular\nuptake of the genes to cancer cells. Cytotoxicity of the dtACPPDs was tested using flow\ncytometry and fluorescent microscopy with BEL-7402 hepatocellular carcinoma cells cultured at\neither pH 6.0 or 7.4 and pretreated with or without MMP-2, showing uptake as high as 90.6% in\nthe presence of MMP-2 at a pH of 6.0 (mimicking slightly acidic tumor microenvironment). In\nvivo testing with mice showed progressive accumulation of dtACPPDs in tumors over time with\nthe smallest accumulation in liver and kidneys in comparison to different control groups. This\nstudy further showcases the benefits of multi-responsive targeting to cancer cells and how its\nincorporation into nanocarrier design can improve overall therapeutic efficacy.73\nIn a study by Mallik and coworkers, they designed nanovesicles responsive to\noverexpression of glutathione (GSH) and MMP-9 in the tumor microenvironment to efficiently\nand selectively deliver the anticancer drug gemcitabine (Gem).74 An MMP-9-cleavable, collagen\nmimetic lipopeptide forms nanovesicles with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine\n(POPC), cholesteryl-hemisuccinate, and the reduction-sensitive, PEGlyated 1-palmitoyl-2-\nPage 10 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n11\noleoyl-sn-glycero-2-phospethanolamine lipid (POPE-SS-PEG5000). The PEGlyation helps instill\nlong circulating characteristics to the nanovesicles while also reducing unintended interactions\nwith circulating proteins. Once at cancer sites, the PEG chains are shed via reduction by GSH,\nwhich then exposes the vesicle to MMP-9 degradation, allowing for release of the contents\ninside. The design and mechanism of release are detailed in Figure 3. In vitro cytotoxicity was\ninvestigated with PANC-1 and MIAPaCa-2 pancreatic cancer cells of Gem-loaded nanovesicles,\nshowing lower cell viability with the PANC-1 line (30-35%), which has a higher expression of\nMMP-9 than MIAPaCa-2 (viability 45-50%), where dose-dependent cytotoxicity evidence is\nseen in Figure 3. In a spheroid culture, the cell viability was similar between free and\nencapsulated Gem in PANC-1 cells, showing encapsulation does not hinder cytotoxicity while\nsimultaneously improving selectivity. An in vivo xenograft mice model with PANC-1 cancer\ncells showed a more significant reduction in tumor growth for the Gem-encapsulated, MMP-9-\nresponsive nanovesicles in comparison to vesicles without an MMP-9 substrate in their design,\nwhich can be seen in Figure 3. The difference in tumor growth and the fact that animals\nremained healthy after treatment illustrates better control of Gem release with MMP-9\nselectivity, highlighting another case where multi-responsiveness significantly improves\nselectivity to cancer cells.74\nPage 11 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n12\nFigure 3. (A) An illustration of nanovesicles and their targeting mechanism that are responsive to the elevated levels of extracellular GSH and MMP-9 by incorporating MMP-9 substrate lipopeptides and reduction-sensitive POPE-SSPEG on their surface. (B) In vitro cell viability data showcasing the concentration dependent decrease in MIAPaCa2 cell viability when treated with free gemcitabine (violet) or gemcitabine-loaded nanovesicles (orange) for 72 hr. (C) Tumor volume percentage increase from xenograft mice model, where blue represents test group (n = 3) treated with MMP-9 substrate-incorporated nanovesicles, red represents group (n = 3) treated with nanovesicles without MMP-9 responsiveness, and black is the control group (n = 3) treated with PBS-loaded nanovesicles (* p < 0.05, ** p < 0.05). Adapted with permission from reference 74. Copyright 2014 American Chemical Society."
    }, {
      "heading" : "Protease-responsiveness for nanostructure formation",
      "text" : "While proteases are often targeting to trigger drug release from various nanomaterials,\nrecent work has been done for the development of nanomaterials systems that use proteases to\ntrigger nanostructure formation to change drug release kinetics or to induce cytotoxicity by their\nassembly. Maruyama and coworkers detail their design of a gelator precursor that undergoes\nintracellular self-assembly to form nanofibers, leading to hydrogelation and inducing cancer cell\ndeath after interacting with MMP-7.75 The gelator precursor, N-palmitoyl-GGGHGPLGARK-\nCONH2 (called ER-C16), design incorporated a 16-carbon alkyl chain to provide hydrophobic\ninteractions to enhance self-assembly in aqueous solutions attached to a peptide sequence\nPage 12 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n13\ncontaining the following: the tetrapeptide sequence GGGH to facilitate assembly as a hydrogen-\nbond acceptor and donor, the MMP-7-cleavable tetrapeptide sequence PLGL for triggering\ngelation, and the cationic peptide sequence RK to prevent ER-C16 from forming nanofibers until\ncleaved off by MMP-7. From TEM imaging, the group found that the gelator precursor forms\nmicelle-like structures until exposed to MMP-7 which initiates self-assembly to nanofibers. The\ncytotoxicity of ER-C16 was investigated in vitro with HeLa cancer cells and MvE normal human\nmicrovascular endothelial cells, where their coculture with exposure to ER-C16 confirmed its\nselectivity to cancer cells due to increased uptake in HeLa cells. The decreased levels of cell\nviability confirmed the relationship between cell death and high intracellular toxicity and\nprovides a therapeutic strategy that cancer cells are unlikely to acquire drug resistance to,\nhighlighting a different but effective use of nanomaterials to selectively target and treat cancer.75\nXu and coworkers have been exploring the concept of enzyme-instructed self-assembly\nfor therapeutics for the past few years, developing a peptide-based system that responds to\nalkaline phosphatase for the formation of hydrogels.76 Their earlier design involves the\nconjugation of the anticancer drug taxol to a succinic acid linker to attach the phosphatase\nsubstrate and self-assembly motif (NapFFKYp) to form a hydrogelator precursor.77 After\nexposure to enzyme activity, the precursors self-assemble into nanofibers and form a\nsupramolecular hydrogel of the taxol derivative, instilling the dual role of delivery vehicle and\ntherapeutic to this molecule. An in vitro study with HeLa cancer cells was conducted and showed\ncomparable cytotoxicity between the precursor and free taxol. Taxol activity is conserved within\nthe hydrogel and the concentration of the precursor molecule can be used to control the release\nrate.77 In a more recent example of their work, Xu and coworkers demonstrated the importance\nof precursor design for enzyme-instructed self-assembly (EISA) for selective killing of cancer\nPage 13 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n14\ncells.78 In this study, they designed and synthesized two different D-tetrapeptides (ffyy and\nanalogues) containing one or two phosphotyrosine residues capped with a napthyl group, where\ndephosphorylation causes the peptides to self-assemble into nanofibers in water and the use of D-\namino acids prevents endogenous protease degradation. The NapFF and NapF are residues with\ngreat self-assembly-promoting motifs because of aromatic-aromatic interactions, and the tyrosine\nresidues provide a site for mono- or diphosphorylation to explore the effect of multiple\nenzymatic triggers on selectivity. TEM images showed that the monophosphorylated precursors\nform nanofibers better due to less solubility than the diphosphorylated precursors and that the\npeptide sequence fyfy has a higher tendency to self-assemble. In vitro cytotoxicity studies were\nconducted with HeLa cervical cancer cells and Saos-2 osteosarcoma cells that showed that\nprecursors inhibited growth of both cell lines by EISA, but response to precursors was dependent\non expression levels of alkaline phosphatase and mechanism of cell death was dependent on the\ncell line. While this lab presents an example of EISA using phosphatases, it highlights the utility\nof nanomaterials, the importance of their design factors, and the variety of other enzymatic\ntargets that can be used for increasing selectivity to cancer cells.78 This strategy offers an\neffective means of overcoming drug resistance and treating multiple cancer lines.79\nPage 14 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n15\nFigure 4. (A) A schematic depiction of the micelle-to-fiber transition the peptide precursors undergo due to the overexpression of MMP-9 by cancer cells, where the anticancer drug doxorubicin is entrapped in the fibrillar structures, thereby creating less mobile depots of the drug. The table represents the different peptide molecules tested in this study. (B) and (C) Impact of peptide design and MMP-9 responsiveness on cancer cell growth of MDA-MB-231-luc-D3H2LN cells using peptides 1a and 2a (as seen in A) with 2.5 mM peptides ± 200 nM doxorubicin. Adapted with permission from reference 81. Copyright 2016 Elsevier Ltd.\nIn another example, Ulijn and coworkers demonstrated the use of proteases to induce a\nmorphological change in nanostructures from micelles to nanofibers to impact drug release\nrates.80 In their initial design, the nanostructures were loaded with the anticancer drug\ndoxorubicin (Dox), and contained the following units: a self-assembly motif for formation of\nnanofibers that provides a hydrophobic binding region for drug candidates (phenylacetyl-FFAG),\nan MMP-9-cleavable sequence, and a hydrophilic peptide sequence (LDD) that favors formation\nof micelles. MMP-9 cleaves off the hydrophilic unit of PhAc-FFAGLDD and confers the\nmicelles into fibers by changing the balance between hydrophobic and hydrophilic interactions,\nallowing for localized and sustained delivery of Dox to cancer cells.80 They also developed a\npeptide-based design (GFFLGLDD) that has the same properties as their first design for the\nreconfiguration of Dox-loaded micelles to nanofibers,81 and both designs are detailed in Figure 4.\nThe reconfiguration of micelles to fibers via MMP-9 hydrolysis was confirmed with AFM and\nTEM for both precursor designs, and aggregation was not impacted by the presence of Dox. An\nin vitro study was conducted with MDA-MB-231-luc-D3H2LN breast cancer cells that showed\nsignificantly reduced cell viability following treatment with both precursors but slightly lower\nwith the peptide-based design (35% vs 37.5% viability, data shown in Figure 4), and confocal\nmicroscopy confirmed uptake of drug by presence of aggregates in cytoplasm and nucleus of\ncells with larger aggregates outside cells, indicating local and sustained delivery were possible\nand effective with these precursor molecules. The same cancer cells were used for a xenograft\nmice model for in vivo efficacy studies, which further validated the selectivity and efficacy of the\nsystem for localized and sustained delivery of Dox.81 This study exemplifies the wide-ranging\nPage 15 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n16\nutility of nanomaterials for cancer therapy and highlights the role proteases can play in formation\nof nanostructures to control drug release, similar to the other works mentioned in this section.\nProtease-responsive nanomaterial systems for diagnostics Extensive work has been conducted over the past decade on the development of\nmolecular probes with sensitivity to proteases overexpressed in cancer cells.51,52,82–85 The\nfollowing proteases whose abnormal activity is associated with cancer or whose activity is an\nindicator of cell death are of particular interest: cathepsins, matrix metalloproteinases, urokinase-\ntype plasminogen activators, and caspases. Cathepsins, MMPs, and uPA were discussed in the\nprevious section for their use in therapeutics, but this can directly translate for targeting with\nimaging agents. Caspases are cysteine-aspartic proteases whose activity is involved in apoptosis\nand inflammation and therefore can be utilized as means of visualizing drug activation and\nefficacy.86 A wide variety of imaging modalities can be used in cancer diagnostics, such as\nfluorescence imaging, MRI, and PET, each offering their own advantages.53 However, different\nimaging techniques do possess their own limitations, and thus different nanomaterial systems\nhave been designed to incorporate more than one modality, allowing for more holistic and\naccurate imaging.42 In this section, we will discuss various nanomaterial systems sensitive to\nthese proteases that use various modalities for the imaging and diagnosis of cancer."
    }, {
      "heading" : "Matrix metalloproteinase-sensitive systems",
      "text" : "Matrix metalloproteinases (MMPs) are popular targets for cancer imaging due to their\noverexpression in many cancer types and easy accessibility based on their location on cell\nsurfaces. Various imaging modalities have been incorporated into MMP-detectable systems, and\nutilization of nanomaterials have improved the efficacy of these systems. For example, NIR\nFRET-based probes conjugated to gold nanoparticles as a fluorescence quencher have been\nPage 16 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n17\nshown to be effective in detection of MMPs and could be used for early diagnosis of cancer.87\nRecent examples of MMP-responsive nanomaterial systems are highlighted here.\nA novel signal-amplifiable self-assembling 19F NMR/MRI probe was developed by\nHamachi and coworkers for imaging MMP-2 activity, where there is no observable signal when\nthe probes are aggregated as nanoparticles but enzyme cleavage-induced disassembly turns the\nsignal “on”.88 The probe itself is comprised of an MMP-2 substrate peptide (GPLGVRG), with\nthe 19F NMR imaging moiety (3,5-bis(trifluoromethyl)benzene) attached to a lysine residue at\nthe C-terminal end and a hydrophobic dodecyl (C12) chain on the N-terminal end. The self-\nassembly into nanoparticles helps resolve issue concerning low sensitivity and poor delivery,\nwhile the 19F MRI modality has high NMR sensitivity with no background noise in vivo, making\nthis a seemingly effective design for tumor imaging. The probes showed in vitro efficacy with\ncancer lines known to secrete MMP-2, but the 19F MRI modality proved to not be as sensitive as\navailable 1H MRI probes, such as those that are gadolinium-based.88\nAnother example of a nanoparticle system was developed by Liu and coworkers,\nconsisting of a novel activatable photoacoustic nanoprobe for in vivo imaging of cancer-\nassociated MMPs.89 The probe is composed of an NIR-absorbing copper sulfide (CuS)\nnanoparticle connected to a black hole quencher (BHQ-3) via an MMP-cleavable peptide linker\n(GPLGVRGKGG), and showed in vitro reactivity to MMP-13. The BHQ-3 molecule and the\nCuS nanoparticle have different absorbance peaks, and comparing signals at these wavelengths\ncan yield photoacoustic imaging of MMP activity. In a mouse model, the nanoparticles are able\nto detect SCC7 breast cancer cells with in vivo photoacoustic imaging, which in comparison to\noptical imaging, the mechanism of photoacoustic imaging offers distinctly improved in vivo\nspatial resolution and exhibits significantly improved tissue penetration. This system offers an\nPage 17 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n18\ninteresting and unique design for an alternative imaging modality to optical fluorescence and\npresents its own advantages for tumor detection and imaging.89\nOver the past decade, Tsien and coworkers have been working on the development of\nmolecular probes for the detection of MMP activity in tumors.90 The basis of their design is the\nincorporation of cell-penetrating peptides (CPPs), which are integral for overcoming multidrug\nresistance in tumor cells.91,92 In their early design, their molecular probe comprised of a\npolyarginine-based CPP (called activatable CPPs), blocked by an inhibitory peptide sequence\nwith negative charges, and a linker between these two domains, which when cleaved by MMP-2\nor MMP-9, allows for the CPP and its cargo, a far-red fluorophore, Cy5, to enter cancer cells.\nThis design showed early promise with great in vivo contrast ratios and elevated standard uptake\nvalues in tumors relative to normal tissue in HT-1080 cancer in mice.90 Further studies showed\nthat these probes can target many xenograft tumor models from different cancer sites and that\nbackground uptake into normal tissue could be decreased by attaching inert macromolecules,\nsparking an investigation into nanomaterial conjugates.93\nFigure 5. (A) Schematic illustration of the activatable cell-penetrating peptide dendrimer (ACPPDs), consisting of a dendrimer (gray circle) covalently attached to the polycationic segments (blue) of the ACPPs, an MMP-2,-9\nPage 18 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n19\ncleavable peptide linker, and polyanionic segments (red) that are released to allow entry of ACPPDs into cells. The payloads stored inside the dendrimers (yellow ovals) can be either Cy5 (ACPPD-Cy5), Gd-DOTA (ACPPD-Gd), or both (dual ACPPD). (B-D) Fluorescence images taken 48 h after injection into mice (with skin removed) with ACPPD-Cy5 or ACPP-Cy5, containing 10 nmol Cy5 each, where yellow arrows point to tumors and D has been brightened to make signal visible, showing enhanced signal from ACPPDs over dendrimers without MMPsensitivity and the free probe. (E) Time course of fluorescence signals in tumors in mice viewed through intact skin, demonstrating enhanced fluorescence signal of MMP-sensitive ACPPDs. (F) Standardized uptake values in solubilized samples of tumor, liver, kidney and muscle 48 h after ACPPD-Cy5 injection and 6 h after ACPP-Cy5 injection with pairwise P values shown for each organ type. Adapted with permission from reference 94. Copyright 2010 National Academy of Sciences.\nThe group developed dendrimeric nanoparticles coated with their activatable CPPs\nlabeled with either Cy5 for fluorescence imaging, gadolinium for MRI, or both.94 The peptide\nsequence, PLDLAG, serves as the MMP-cleavable linker, where cleavage separates the\ninhibitory domain from the loaded, CPP-conjugated polyamidoamine (PAMAM) dendrimer\nnanoparticle. The schematic of the nanoparticles, in vivo fluorescence images, and time-\ndependence and biodistribution data are detailed in Figure 5. The nanoparticles had significantly\nhigher uptake in tumors than the activatable CPPs alone, allowed for fluorescence detection of\ntumors as small as 200 µm, and deposited high levels of Gd in tumors yielding MRI T1 contrast\nthat lasts several days after injection. The nanoparticle conjugation reduces background noise\nand improves uptake into tumor cells. Loading of the dendrimer nanoparticles with MRI and\nfluorescence imaging modalities improves its utility by giving it the advantages of both\ntechniques, finding uses in MRI-guided staging and fluorescence-guided resection for many\ndifferent cancer lines in various parts of the body.94 The group has also applied this\nnanotechnology to the MRI and fluoroscence imaging of atherothrombosis and stroke with\ndifferent enzyme targets, and incorporated integrin αvβ3-targeting in addition to MMP-2\nsensitivity for improved sensitivity and selectivity of their probe, showcasing the ubiquity of\nprotease-responsive nanomaterials in the imaging of many diseases.8,95–97\nPage 19 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n20"
    }, {
      "heading" : "Cathepsin-sensitive systems",
      "text" : "Many groups have conducted work over the past decade exploring the development of\ncathepsin-sensitive probes. Many probes have incorporated various imaging modalities, such as\noptical imaging with fluorescence resonance energy transfer (FRET)-based probes or magnetic\nresonance imaging, and later have been combined with nanomaterials to improve signal ratios\nand targeting.22,82,98\nMolecular probes with cathepsin-sensitivity designed by some groups have showed a lot\nof potential for clinical applications. Very recently, the labs of Kirsch and Brigman have\ndeveloped a near-infrared FRET-based probe with sensitivity to various cathepsins, particularly\ncathepsin S, that have progressed to ex vivo first-in-human phase 1 clinical trials in patients with\nsoft tissue sarcoma or breast cancer.99 Showing that their probe design is safe for use in humans\nand yields tumor-specific fluorescent signals, these probes could very well make it to a clinical\nsetting. This design however lacks the advantages offered by nanomaterials, and successful\ncompletion of clinical trials could suggest nanomaterial systems may be just as effective for\ncancer imaging, if not more.\nAnother recent example of a cathepsin-responsive nanomaterial system was developed by\nCui and coworkers, compromising of molecular probes that self-assembles into a supramolecular\nstructure they called nanobeacons.100 Their nanobeacons compromise of hydrophobic and\nhydrophilic domains, where the amphiphilic nature helped to induce the self-assembly of the\nprobes into core-shell micelles in aqueous environments. The hydrophobic domain consists of a\nfluorescent green dye, 5-carboxyfluorescein (5-FAM) and a black hole quencher, BHQ-1,\nwhereas the hydrophilic domain consists of an HIV-1 derived cell-penetrating peptide sequence,\nTat48-60, where the charged residues allow the nanobeacons to be responsive to changes in pH.\nThe fluorophore and quencher are held in close proximity for FRET by a cathepsin B (CatB)\nPage 20 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n21\ncleavable linker (GFLG sequence). The imaging modality is contained within the nanobeacon\nafter spontaneous assembly into micelles and thus protected from CatB cleavage, until the\nnanobeacons are converted back to their monomeric form by pH or dilution to below its critical\nmicellization concentration (CMC). The nanobeacons proved effective after incubation with\nMCF-7 human breast cancer cells in vitro, where confocal imaging and flow cytometry showed\nlocalization of the fluorescence signal in lysosomes and an increasing signal over time.100\nThe group continued studying their nanobeacons by investigating the role that their shape\nand surface chemistry play on their uptake and activity in vitro.101 This design incorporates the\nsame quencher, fluorophore, and CatB-degradable linker, but instead uses a GNNQQNY central\nassembly sequence derived from Sup357-13 that can spontaneously associate into different\nmorphologies based on temperature and incubation time in aqueous solutions. This sequence was\nmodified with either three lysine or three glutamic acid residues for either positive or negative\nsurface charge, and the probes were allowed to form either spherical or filamentous shapes. By\nobserving cellular uptake by PC3-Flu metastatic human prostate cancer cells, they were able to\nshow that positively-charged nanobeacons had much higher uptake efficiency as opposed its\nmonomeric form, making this combination of shape and surface chemistry most-suited for\nintracellular sensing. The nanobeacon filaments had significantly lower internalization by cancer\ncells, making them for suitable for sensing extracellular proteases, like MMPs and uPA. The\nmolecular design, nanobeacon characteristics, and confocal images and flow cytometry data of\ncellular uptake can be seen in Figure 6.101 While in vivo work was not conducted, these studies\nare revealing of a nanoscale system with potential for significant tumor accumulation and\naccurate sensing based on the optimal shape and surface chemistry for their target protease.\nPage 21 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n22\nFigure 6. (A) The molecular design of the two studied molecular beacons capable of self-assembling, SFB-K and SFB-E, which are composed of the following design elements: the Black Hole Quencher-1 (BHQ-1), the fluorophore 5-FAM, the degradable peptide linker for cathepsin B specificity GFLG, and the central assembly regulating sequence GNNQQNY terminated with either three lysine (K) or glutamic acid (E) residues. (B) A schematic illustration of molecular beacons’ assembly into spherical or filamentous supramolecular nanobeacons based on assembly temperature and incubation time. (C) Cellular uptake efficiency by cancer cells of beacons, varying in surface charge, shape, and assembly state, as characterized by flow cytometry: fluorescence intensity measurements (left), flow cytometry spectra comparing fluorescence intensity of SFB-K (top right) and SFB-E (bottom right). (D) Confocal laser scanning microscopy of PC3-Flu cells after 1 h incubation with 5 µM of nanobeacons with different surface charges and shapes (a-f). Adapted with permission from reference 101. Copyright 2016 American Chemical Society."
    }, {
      "heading" : "Urokinase-sensitive systems",
      "text" : "Urokinase-type plasminogen activator (uPA) of the urokinase-type plasminogen activator\nsystem is an attractive target for cancer sensitivity due to its overexpression in a handful of\ncancer lines and its presence on the exterior of the cell membrane. Over the past few years,\nmolecular probes and nanomaterial systems responsive to uPA activity, particularly for breast\ncancer imaging, have been developed.102 For example, Law and coworkers developed a self-\nassembled nanofiber from a PEG2000-peptide conjugate. 103 The uPA substrate, SGRSANA,\nserved as a linker between the hydrophobic D-amino acid domain and the hydrophilic PEG\nPage 22 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n23\ndomain with conjugated fluorescein isothiocyanate (FITC) for fluorescence imaging., where in\nthe self-assembled state, no signal could be detected due to aggregation-induced quenching.\nWhile only a proof-of-principle study, this group showed the applicability of their technology to\nin vivo uPA activity imaging for cancer detection.103\nContinuing with this concept, Law and coworkers developed an NIR molecular probe\nwith a similar structure as mentioned before, with a PEG-based hydrophilic domain conjugated\nto the near-IR dye, NIR664, linked by a uPA-cleavable peptide sequence to a hydrophobic D-\namino acid sequence, which allows for self-assembly into nanofibers in aqueous solution.104\nThese nanofibers were able to detect uPA activity from several human cancer cell lines in vitro\nwith very high fluorescence signals, giving more evidence to the applicability of these nanofibers\nfor the diagnosis and even treatment of cancer based on different expression levels of uPA\nactivity.104\nAnother interesting nanomaterial design for cancer imaging via uPA proteolysis was\ndeveloped by Stevens and coworkers.105 They designed multiplex assay nanoparticles that are\nable to detect uPA activity and human epidermal growth factor receptor 2 (Her2) kinase activity,\nwhich are both overexpressed in breast cancer. Their system consists of two quantum dot (QD)\npopulations with different emission wavelengths and orthogonal surface functionalizations for\nsignal independence between the two different enzymes. The QDs serve not only as a reporter\nmolecule but also as a scaffold for conjugates attached via enzyme-specific linker peptide\nsequences. The QD, QD525, was used for uPA-sensing and was attached to the uPA-cleavable\nlinker sequence, SGRSAN, which is covalently coupled to a gold nanoparticle that quenches the\nQD signal until cleaved away by uPA. A similar design was implemented for Her2 kinase\ndetection, where phosphorylation of the Her2 kinase-sensitive linker induces FRET-based\nPage 23 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n24\nquenching. This system is the first demonstration of a nanoparticle-based activity assay being\nable to simultaneously sense the activity of two different classes of enzymes, which can provide\nprognostic information for breast cancer patients.105"
    }, {
      "heading" : "Caspase-sensitive systems",
      "text" : "Caspases are useful imaging targets due to their role in programmed cell death, like\napoptosis, and inflammation. The information obtained by visualizing when cells undergo\napoptosis can elucidate information about the pharmacokinetics of a certain therapeutic and\nallow for long-term monitoring of drug response in a patient.86 An example of a caspase-\nsensitive nanomaterial system is described here for visualization of cancer cell response to\ndifferent chemotherapeutics.\nA caspase-sensitive nanoaggregation fluorescent probe, called C-SNAF, was developed\nby Rao and coworkers that uses a biorthogonal cyclization reaction that triggers self-assembly\nand yields an aggregation-induced NIR fluorescence signal.106 The C-SNAF probe contains D-\ncysteine and 2-cyano-6-hyrdoxyquinoline (CHQ) moieties that are linked to an amino luciferin\nscaffold. Additionally, it contains a L-DEVD capping sequence and a disulfide bond that are\nrequired for a two-step activation with caspase-3/7-mediated cleavage and an intracellular thiol-\nmediated reduction, which consequently promotes aggregation and gives NIR signal from Cy5.5\ndye. Figure 7 details the molecular design of C-SNAF and the mechanism of nanoaggregation in\nlive versus apoptotic tumor cells. As indicated by fluorescence and 3D-SIM imaging in\nDoxorubicin-treated mice tumor models, this probe is able to penetrate into tumor tissue after IV\ninjection and successfully report tumor-cell death induced from chemotherapy in vivo. The\nprobes are rigid and hydrophobic after undergoing cyclization which promotes nanoaggregation,\nwhere they are retained in apoptotic cells and give high imaging contrast for detection of\ntherapeutic-response.106\nPage 24 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n25\nFigure 7. (A) Molecular design and the proposed conversion of C-SNAF into C-SNAF-cycl via reduction and caspase-3/7 activation of the biorthogonal intermolecular cyclization reaction, which is then followed by the selfassembly into nanoaggregates: green represents the capping peptide residues; dark orange, amino group of Dcysteine; light orange, thiol group of D-cysteine; yellow, thioethyl masking group, blue, the CHQ group; and red, the red NIR fluorophore Cy5.5. (B) An illustration of the mechanism of C-SNAF for in vivo imaging of tumor response following chemotherapy in living versus apoptotic cancer cells. (C) Chemical structures of probes used as controls for this study. Adapted with permission from reference 106. Copyright Nature Chemistry, 2014 Macmillan Publishers Ltd.\nRao and coworkers have expanded on this design to incorporate different imaging\nmodalities. A Gd-based MRI probe, called C-SNAM, was developed, with prolonged\naccumulation in chemotherapy-induced apoptotic cells and tumors with significantly brighter\ncontrast between treated and non-treated tumors.107 Additionally, a 18F-based PET probe was\ndeveloped which also had significantly higher tumor signal and tumor-to-muscle ratios in murine\nmodels in response to tumor therapy.108,109 The group also applied this technology for apoptosis\nimaging with caspase-activity in arthritis,110 highlighting the vast applicability of this probe\ndesign to imaging a drug efficacy for many diseases.\nPage 25 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n26\nProtease-responsive nanomaterial systems for theranostics Many promising and efficacious systems have been developed for cancer imaging and\ndrug delivery, which has helped sparked interest in studying and designing theranostic systems.\nThese systems allow for simultaneous imaging and treatment and offer a means of visualizing\nthe pharmacokinetics and biodistribution of therapeutics used for a cancer patient.27 Theranostic\nnanomaterials can benefit from the incorporation of protease-sensitivity for improved selectivity,\nbut multi-responsive systems that include protease-responsiveness have become popular for\ndesigning more efficacious drug delivery and imaging systems. The nanomaterial systems can\nrespond to other factors in the tumor microenvironment, such as cell-surface receptors,111,112\npH,73,113,114 and other classes of enzymes,115 thereby increasing sensitivity and selectivity and\nthus improving the overall efficacy of the cancer treatment. In this section, we will be discussing\ntheranostic nanomaterial systems responsive to protease activity, including some examples that\nare sensitive to other factors in the tumor microenvironment.\nAn early example of the development of a theranostic probe was by Zheng and coworkers\nthat showcased the possibility and advantages of simultaneous imaging and treatment of tumor\ncells.116 Their probe is capable of photodynamic therapy for cancer, where photodamage is\ninduced via irradiation, and subsequently gives a near-infrared fluorescence signal to indicate\nsuccessful induction of apoptosis. The molecular design contains the photosensitizing agent,\npuropheophorbide a (Pyro), dual fluorescence and singlet oxygen quencher, BHQ-3, and a\ncaspase-3-responsive peptide linker sequence, GDEVDGSGK. When tumor cells are irradiated\nwith light in the presence of these molecular beacons, the photosensitizer converts oxygen into\nsinglet oxygen, which destroys mitochondrial membranes and triggers apoptosis; therefore,\ncaspase-3 expression will increase and act to cleave the linker sequence and give a detectable\nsignal to indicate cell death. This design showed efficacy in vitro and was later shown to have in\nPage 26 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n27\nvivo efficacy after the incorporation of folate into the molecular design to target overexpressed\nfolate receptors on the surfaces of cancer cells to induce endocytosis and improve selectivity to\ntumor tissue.116,117 Further work was done to improve design by instead using an MMP-7-\nsensitive linker for targeting to tumor cells, which simplified molecule complexity and synthesis\nrequirements while also yielding comparable selectivity and therapeutic efficacy as earlier\ndesigns in vitro and in vivo.118 These beacons showcased mitigated nonspecific accumulation and\nenhanced tumor cell death in human breast carcinoma cells (MT-1 line) that commonly produce\nspinal metastases, where risks of spinal cord damage are very high, offering a safe approach of\nselective photodynamic therapy while preserving critical tissues.119 Their beacon design has\nshown efficacy for other types of cancer metastases without the incorporation of a nanomaterial,\nwhich could be useful in improving tumor accumulation, but regardless, the molecular beacons\nexemplify the utility of theranostics for cancer treatment.120\nWhile the previously discussed example detailed an effective theranostic probe, using\nnanomaterials can prolong circulation time, reduce possibility of nonspecific activation, and\nincrease accumulation at tumor sites.4,47 The labs of Kim and Ahn designed gold nanorods with\nMMP-sensitivity for cancer treatment and imaging.121 When irradiated, the gold nanorods absorb\nthe near-infrared laser light and convert it into heat as a means of hyperthermal therapy for\ncancer cells, which are more susceptible to treatment due to their lower heat tolerance from poor\nblood supply. The near-infrared dye Cy5.5 was conjugated to the surface of the nanorods via the\nMMP-sensitive peptide linker sequence, GPLGVRGC, which is responsive to a variety of\nMMPs. Gold is a popular material for imaging due to its exhibition of surface plasmon\nresonance, where it can serve as a fluorescence quencher as it does in this design. These\nnanorods were studied with HeLa cells in vitro and with SCC-7 tumors in mice, where the\nPage 27 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n28\nnanorods showed the ability to effectively kill cancer cells very rapidly, as temperatures could\nincrease over 45°C in little as four minutes. However, the external skin of the mice was burned at\ntumor sites and nonspecific damage seems unavoidable with this design. Only the imaging\nfunction of this design is sensitive to the overexpressed MMP activity in tumors and the\ntherapeutic function can be delivered regardless of MMP presence; therefore, further\nmodifications could be added for improving selectivity. However, this does represent a unique\ntherapeutic approach, and it showcases the importance of selectivity and the utility that gold\npossesses for theranostic applications.121\nIn another example of utilizing inorganic nanostructures, Cheng and Xing report the\ndesign of a protease-responsive, core-shell, dual-imaging magnetic silica-coated nanoparticles.122\nThe anticancer-drug, doxorubicin (Dox), is conjugated to a cathepsin B-cleavable peptide\nsequence (FK) with a para-aminobenzyloxycarbonyl (PABC) linker, and through click\nchemistry, they are attached to the surface of uniform silica-coated, superparamagnetic iron\noxide nanoparticles via an azido-dPEG4 linker. Doxorubicin is a red fluorescent drug, which in\nconjunction with the iron oxide nanoparticles, allows for dual-modality imaging of both MRI and\noptical imaging. With confocal microscopy and MRI spectroscopy, they showed highly efficient\nrelease of Dox upon interaction with cathepsin B in HT-29 cancer cells in vitro. Cell viability\nwas comparable between nanoparticle-treated and free drug-treated cells but was much higher\nfor the nanoparticle-treated negative control cells than free drug, indicating that the nanoparticles\nfunction to give selective tumor intracellular drug delivery and imaging while keeping healthy\ntissues safe.122 This system, while showcasing dual-modality for imaging, also contains an\nintrinsically theranostic moiety in Dox, which greatly improves efficacy as a theranostic for\ncancer.\nPage 28 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n29\nExpanding upon this notion of intrinsically theranostic systems, by using moieties\ncapable of both imaging and therapy in the design of nanomaterial systems for cancer, there is no\nlonger a need to compromise on the extent of loading between imaging and therapeutic moieties\nnor long lag time periods present between drug activation and corresponding optical signal. Cui\nand coworkers developed, to the best of their knowledge, the first enzyme-specific Dox prodrug\nconjugated with a dark chromophore quencher capable of both diagnostic and therapeutic\nfunctions.123 Their FRET-based molecular probe contains red-fluorescent anticancer drug, Dox, a\nblack hole quencher (BHQ-2) conjugated via a cathepsin B-sensitive peptide linker (GFLG), and\na cell-penetrating peptide sequence (R8) to help circumvent drug resistance in some cancer lines.\nConfocal images taken of NCI/ADR-Res ovarian cancer cells, which are resistant to Dox,\nindicate the efficacy of the drug-beacons to simultaneously image and treat cancer while\novercoming drug resistance, as the drug-beacons showed significantly better cytotoxicity in\ncomparison to free Dox. While this system does not incorporate any nanomaterials, the beacons\ncould be modified to self-assemble into nanostructures for in vivo efficacy. The intrinsic\ntheranostic ability of this system simplifies molecular design and offers sufficient drug loading\nwith direct visualization of drug activation.123\nIn another example, Rao and Daldrup-Link report the design of a novel, multifunctional\ntheranostic nanoparticle with the capability to release drugs via enzymatic cleavage and to give\nMR and fluorescence imaging of drug delivery in vivo.124 The design incorporates a magnetic\niron oxide nanoparticle, ferumoxytol, conjugated to an MMP-14-responsive peptide sequence\nthat holds the green-fluorescent dye, fluorescein isothiocyanate (FITC), and a vascular disrupting\nagent, azademethylcolchicine (ICT), creating a theranostic probe they call CLIO-ICTs. The\nmolecular design and mechanism of action of CLIO-ICTs are detailed in Figure 8. Upon treating\nPage 29 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n30\nMMP-14-positive MMTV-PyMT breast cancer cells with CLIO-ICTs, significant cell death was\nobserved in vitro, but not for cells treated with ferumoxytol alone nor MMP-14-negative\nfibroblasts, indicating MMP-14-sensitivity is needed for effective delivery. Tumor-bearing mice\nwere given IV injections of the nanoparticles, and subsequent MR imaging showed significant\ntumor accumulation of CLIO-ICT and was confirmed with histopathology staining, further\ndemonstrating the selectivity of the nanoparticles to tumors and not healthy tissues. MR images\nand corresponding signal data are given in Figure 8. The dual-modality imaging offers the\nadvantages of both techniques in a single probe that also treats cancer, the nanostructure design\nincreases tumor retention, and together, improve the overall antitumor efficacy.124\nFigure 8. (A) A schematic illustration representing the activation of the theranostic nanoparticles, CLIO-ICT, by MMP-14 cleavage. The iron oxide nanoparticle (IONP) is shown in orange; the prodrug azademethylcolchicine (ICT) is shown in red, and its product after MMP-14 degradation is shown in magenta; the MMP-14 sensitive peptide linker is shown in blue; and the green fluorophore, fluorescein isothiocyanate (FITC), is shown in green. (B) Synthesis pathway for the CLIO-ICT theranostic nanoparticles, highlighting cross-linking and ICT prodrug addition. (C) Axial T2-weighted MR images of MMTV-PyMT mammary tumors before and after a single IV injection of either 0.6 M (Fe) solution of fermyoxytol, 0.4 M solution of CLIO-ICT, 0.29 mM solution of ICT, or PBS, where contrast agent accumulation is indicated as a negative (dark) signal enhancement of the tumors. (D) The corresponding MR signal enhancement data of tumors in C quantified as ∆R2 = (R2pre – R2post). Adapted with permission from reference 124. Copyright 2014 John Wiley and Sons.\nPage 30 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n31\nWhile protease-responsiveness is an effective means of increasing tumor selectivity,\nincorporating other factors of the tumor microenvironment alongside protease-activation can\nfurther improve cancer targeting. The groups of Mao and Yang report on the design and\neffectiveness of urokinase plasminogen activator receptor (uPAR)-targeted, cathepsin B-\nsensitive magnetic iron oxide nanoparticles (IONPs) that carry the chemotherapeutic drug\ngemcitabine (Gem).125 The iron oxide nanoparticles are conjugated with an amino-terminal\nfragment peptide (ATF) of the receptor-binding domain of uPA and Gem via a cathepsin B-\ncleavable peptide linker (GFLG) on their surfaces, with nanoparticles being called ATF-IONP-\nGem. The molecular design specifics and means of activation are detailed in Figure 9. The\nnanoparticles showed higher drug release in more acidic surroundings, which is representative of\nthe lysosomal and endosomal environments that contain cathepsins. In vitro and in vivo studies\nof ATF-IONP-Gem efficacy with the MIA PaCa-2 human pancreatic cancer cell line showed that\nfree Gem only inhibited tumor growth by 30%, whereas ATF-IONP-Gem exhibited\napproximately 50% tumor growth inhibition in xenograft mice. Cell viability and tumor weight\ndata post-treatment are provided in Figure 9. The delivery of ATF-IONP-Gem and presence of\nresidual tumors could then be detected noninvasively by MRI using both T2-weighted and T1-\nweighted ultrasound echo time imaging, allowing for monitoring and assessment of treatment\nefficacy. The significant difference in tumor treatment between nanoparticles with only cathepsin\nB-sensitivity and those with uPAR and cathepsin B-targeting emphasizes the increasing\nselectivity to tumor tissue by incorporating responsiveness to multiple factors in the tumor\nmicroenvironment, which is promising for the development of safer and more personalized\nmedicine in future via theranostics.125\nPage 31 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n32\nFigure 9. (A) An illustration of the conjugation of the amino-terminal fragment peptides of the receptor-binding domain of uPA (ATF), the cathepsin B-sensitive linker, and anticancer drug gemcitabine (GFLG-Gem) conjugates to the surface of iron oxide nanoparticles (IONPs), forming ATF-IONP-Gem. (B) A schematic representation of the release of gemcitabine after cathepsin B-cleavage from ATF-IONP-Gem. (C) Data from a cell proliferation assay conducted on MIA PaCa-2 cells after 4 h treatment with free Gem, IONP-Gem, or ATF-IONP-Gem followed by 72 h incubation, indicating high reduction in cell viability from conjugation of Gem to IONPs with targeting for uPAR and cathepsin B. (D) Further evidence of improved efficacy of ATF-IONP-Gem from tumor xenograft mice models by comparing mean tumor weights and individual tumor weight distributions of mice in each group represented by colored symbols. Adapted with permission from reference 125. Copyright 2013 American Chemical Society."
    }, {
      "heading" : "Conclusion",
      "text" : "A better understanding of the molecular basis of many diseases has been developed over\nthe years, particularly in regards to cancer, leading to the identification of microenvironment\nfactors and cellular features that are representative of diseased tissue. These factors have been\nsignificantly beneficial in improving the selectivity and efficacy of imaging agents and\ntherapeutics to tumor tissues. Proteases, which are overexpressed in many cancer lines at various\ncellular locations, play important roles in cancer progression and, therefore, are attractive targets.\nNanotechnology can further improve the efficacy of imaging agents and pharmaceuticals, where\ndesign factors can be modified to influence the characteristics of nanomaterials and impact the\ndelivery properties, primarily through improvement of the pharmacokinetic profile and\nPage 32 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n33\nbiodistribution of free probes and drugs. The combination of imaging and therapeutics has\nopened a new field of medicine called theranostics, producing systems that possess the ability to\nimage drug delivery, drug release, and drug efficacy using a single entity. Incorporating\nprotease-responsiveness into a theranostic platform creates new materials that can assist with\nearly stage cancer diagnosis, give an accurate evaluation of cancer progression, and\nnoninvasively provide real time information to healthcare providers to choose appropriate\nmedical treatments. Such multi-functional platforms can increase successful clinical outcomes\nand pave the way toward personalized medicine. In this review, we have briefly discussed recent\nexamples of therapeutic, diagnostic, and theranostic nanomaterial systems that have proven\nuseful for cancer treatment and show promise that these systems can be translated into a clinical\nsetting in the near future.\nThe incorporation of protease-sensitivity and nanotechnology already address several\nissues faced in delivery by prolonging circulation and improving tumor accumulation, specific\ntumor targeting, and tumor penetration. The selection of the proper protease target is critical in\ntheranostic system design, as some proteases may prove more beneficial for imaging or drug\ndelivery based on their location in, on, or around cancer cells. Signals and delivery are\nsusceptible to protease location, quantity, and activity which can vary and are not uniform\namongst all cancer types. Multiple modalities for imaging can give the benefits of multiple\ntechniques in a single probe, yielding more information, but this can complicate the\nmanufacturing process and reproducibility of signals. While targeting multiple environmental\nfactors increases selectivity, finding the optimal combination to maximize selectivity and\npreserve healthy tissues is necessary. Additionally, the sequence in which the system will\nrespond to these factors must be considered for the highest efficacy. Trade-offs occur when\nPage 33 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n34\ncombining imaging and therapy, such as compromising on the loading of one agent over the\nother, accounting for the difference in the necessary concentration for good imaging contrast and\ntherapeutic response, and considering the optimal circulation times between different agents\n(imaging agents benefit from faster clearance whereas therapeutics benefit from sustained\ndelivery). These issues can be addressed by using molecules that possess both imaging and\ntherapeutic properties and work should be done to develop these types of theranostic probes.\nAddressing these challenges will yield better clinical outcomes for cancer treatment and bring us\ncloser to personalized medicine."
    }, {
      "heading" : "Acknowledgements",
      "text" : "This invited contribution is part of the I&EC Research special issue for the 2017 Class of\nInfluential Researchers. This work was supported by the National Science Foundation (DMR\n1255281) and the National Institutes of Health (NIH/R21CA191740). We would also like to\nthank Daryl Anderson for his contribution in the development of our illustrations.\nPage 34 of 45\nACS Paragon Plus Environment\nIndustrial & Engineering Chemistry Research\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59\n35"
    } ],
    "references" : [ {
      "title" : "Multifunctional, Stimuli-Senstive Nanoparticle Systems for Drug Delivery",
      "author" : [ "V.P. Torchilin" ],
      "venue" : "Nat. Rev. Drug Discov. 2014,",
      "citeRegEx" : "Torchilin,? \\Q2014\\E",
      "shortCiteRegEx" : "Torchilin",
      "year" : 2014
    }, {
      "title" : "Targeting Cathepsin E in Pancreatic Cancer by a Small Molecule Allows In Vivo Detection",
      "author" : [ "E.J. Keliher", "T. Reiner", "S. Earley", "J. Klubnick", "C. Tassa", "A.J. Lee", "S. Ramaswamy", "N. Bardeesy", "D. Hanahan", "R.A. Depinho", "C.M. Castro", "R. Weissleder" ],
      "venue" : "Neoplasia 2013,",
      "citeRegEx" : "Keliher et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Keliher et al\\.",
      "year" : 2013
    }, {
      "title" : "Enzyme-Responsive Nanoparticles for Drug Release and Diagnostics",
      "author" : [ "R. De La Rica", "D. Aili", "M.M. Stevens" ],
      "venue" : "Adv. Drug Deliv. Rev. 2012,",
      "citeRegEx" : "Rica et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Rica et al\\.",
      "year" : 2012
    }, {
      "title" : "Enzyme-Responsive Nanomaterials for Controlled Drug Delivery",
      "author" : [ "Q. Hu", "P.S. Katti", "Z. Gu" ],
      "venue" : "Nanoscale 2014,",
      "citeRegEx" : "Hu et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Hu et al\\.",
      "year" : 2014
    }, {
      "title" : "Peptide-Based Imaging Agents for Cancer Detection",
      "author" : [ "X. Sun", "Y. Li", "T. Liu", "Z. Li", "X. Zhang", "X. Chen" ],
      "venue" : "Adv. Drug Deliv. Rev. 2016 DOI: 10.1016/j.addr.2016.06.007",
      "citeRegEx" : "Sun et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Sun et al\\.",
      "year" : 2016
    }, {
      "title" : "Peptide-Based Molecular Beacons for Cancer Imaging and Therapy",
      "author" : [ "T.W.B. Liu", "J. Chen", "G. Zheng" ],
      "venue" : "Amino Acids 2011,",
      "citeRegEx" : "Liu et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 2011
    }, {
      "title" : "The Role of Proteolytic Enzymes in Cancer Invasion and Metastasis",
      "author" : [ "M.J. Duffy" ],
      "venue" : "Clin. Exp. Metastasis 1992,",
      "citeRegEx" : "Duffy,? \\Q1992\\E",
      "shortCiteRegEx" : "Duffy",
      "year" : 1992
    }, {
      "title" : "Gelatinase Activity Imaged by Activatable Cell-Penetrating Peptides in Cell-Based and in Vivo Models of Stroke",
      "author" : [ "S. Chen", "J. Cui", "T. Jiang", "E.S. Olson", "Q.-Y. Cai", "M. Yang", "W. Wu", "J.M. Guthrie", "J. Robertson", "S.A. Lipton", "L. Ma", "R.Y. Tsien", "Z. Gu" ],
      "venue" : "J. Cereb. Blood Flow Metab. 2015,",
      "citeRegEx" : "Chen et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Chen et al\\.",
      "year" : 2015
    }, {
      "title" : "Magnetic Resonance Imaging of Stem Cell Apoptosis in Arthritic Joints with a Caspase Activatable Contrast Agent",
      "author" : [ "H. Nejadnik", "D. Ye", "O.D. Lenkov", "J.S. Donig", "J.E. Martin", "R. Castillo", "N. Derugin", "B. Sennino", "J. Rao", "H. Daldrup-Link" ],
      "venue" : "ACS Nano 2015,",
      "citeRegEx" : "Nejadnik et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Nejadnik et al\\.",
      "year" : 2015
    }, {
      "title" : "The Enhanced Permeability and Retention (EPR) Effect in Tumor Vasculature: The Key Role of Tumor-Selective Macromolecular Drug Targeting",
      "author" : [ "H. Maeda" ],
      "venue" : "Advan. Enzym. Regul 2001,",
      "citeRegEx" : "Maeda,? \\Q2001\\E",
      "shortCiteRegEx" : "Maeda",
      "year" : 2001
    }, {
      "title" : "A Nanoparticle-Based Strategy for the Imaging of a Broad Range of Tumours by Nonlinear Amplification of Microenvironment Signals",
      "author" : [ "Y. Wang", "K. Zhou", "G. Huang", "C. Hensley", "X. Huang", "X. Ma", "T. Zhao", "B.D. Sumer", "R.J. Deberardinis", "J. Gao" ],
      "venue" : "Nat. Mater. 2014,",
      "citeRegEx" : "Wang et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2014
    }, {
      "title" : "NearInfrared pH-Activatable Fluorescent Probes for Imaging Primary and Metastatic Breast Tumors",
      "author" : [ "H. Lee", "W. Akers", "K. Bhushan", "S. Bloch", "G. Sudlow", "R. Tang", "S. Achilefu" ],
      "venue" : "Bioconjug. Chem. 2011,",
      "citeRegEx" : "Lee et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Lee et al\\.",
      "year" : 2011
    }, {
      "title" : "Tumor Fibroblast Specific Activation of a Hybrid Ferritin Nanocage-Based Optical Probe for Tumor Microenvironment Imaging",
      "author" : [ "T. Ji", "Y. Zhao", "J. Wang", "X. Zheng", "Y. Tian", "G. Nie" ],
      "venue" : "Small 2013,",
      "citeRegEx" : "Ji et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Ji et al\\.",
      "year" : 2013
    }, {
      "title" : "Supramolecular Nanostructures Formed by Anticancer Drug Assembly",
      "author" : [ "A.G. Cheetham", "P. Zhang", "Y.-A. Lin", "L.L. Lock", "H. Cui" ],
      "venue" : "J. Am. Chem. Soc",
      "citeRegEx" : "Cheetham et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Cheetham et al\\.",
      "year" : 2013
    }, {
      "title" : "Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment",
      "author" : [ "B. Chen", "W. Dai", "B. He", "H. Zhang", "X. Wang", "Y. Wang", "Q. Zhang" ],
      "venue" : "Theranostics 2017,",
      "citeRegEx" : "Chen et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Chen et al\\.",
      "year" : 2017
    }, {
      "title" : "Stimuli-Responsive Nanomaterials for Therapeutic Protein Delivery",
      "author" : [ "Y. Lu", "W. Sun", "Z. Gu" ],
      "venue" : "J. Control. Release",
      "citeRegEx" : "Lu et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Lu et al\\.",
      "year" : 2014
    }, {
      "title" : "Stimuli-Responsive Nanocarriers for Drug Delivery",
      "author" : [ "S. Mura", "J. Nicolas", "P. Couvreur" ],
      "venue" : "Nat. Mater. 2013,",
      "citeRegEx" : "Mura et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Mura et al\\.",
      "year" : 2013
    }, {
      "title" : "Protease-Activated Drug Development",
      "author" : [ "K. Young Choi", "M. Swierczewska", "S. Lee", "X. Chen" ],
      "venue" : "Theranostics 2012,",
      "citeRegEx" : "Choi et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Choi et al\\.",
      "year" : 2012
    }, {
      "title" : "Imaging of Differential Protease Expression in Breast Cancers for Detection of Aggressive Tumor Phenotypes",
      "author" : [ "C. Bremer", "C.-H. Tung", "A. Bogdanov", "R. Weissleder" ],
      "venue" : "Radiology",
      "citeRegEx" : "Bremer et al\\.,? \\Q2002\\E",
      "shortCiteRegEx" : "Bremer et al\\.",
      "year" : 2002
    }, {
      "title" : "Tumor-Specific Formation of Enzyme-Instructed Supramolecular Self-Assemblies as Cancer Theranostics",
      "author" : [ "P. Huang", "Y. Gao", "J. Lin", "H. Hu", "H.-S. Liao", "X. Yan", "Y. Tang", "A. Jin", "J. Song", "G. Niu", "G. Zhang", "F. Horkay", "X. Chen" ],
      "venue" : "ACS Nano 2015,",
      "citeRegEx" : "Huang et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Huang et al\\.",
      "year" : 2015
    }, {
      "title" : "Noninvasive Optical Imaging of Cysteine Protease Activity Using Fluorescently Quenched ActivityBased Probes",
      "author" : [ "G. Blum", "G. Von Degenfeld", "M.J. Merchant", "H.M. Blau", "M. Bogyo" ],
      "venue" : "Nat. Chem. Biol",
      "citeRegEx" : "Blum et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Blum et al\\.",
      "year" : 2007
    }, {
      "title" : "Cathepsin Cysteine Proteases Are Effectors of Invasive Growth and Angiogenesis during Multistage Tumorigenesis",
      "author" : [ "J.A. Joyce", "A. Baruch", "K. Chehade", "N. Meyer-Morse", "E. Giraudo", "F.-Y. Tsai", "D.C. Greenbaum", "J.H. Hager", "M. Bogyo", "D. Hanahan" ],
      "venue" : "Cancer Cell 2004,",
      "citeRegEx" : "Joyce et al\\.,? \\Q2004\\E",
      "shortCiteRegEx" : "Joyce et al\\.",
      "year" : 2004
    }, {
      "title" : "Roles of Matrix Metalloproteinases in Cancer Progression and Their Pharmacological Targeting",
      "author" : [ "C. Gialeli", "A.D. Theocharis", "N.K. Karamanos" ],
      "venue" : "FEBS J. 2011,",
      "citeRegEx" : "Gialeli et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Gialeli et al\\.",
      "year" : 2011
    }, {
      "title" : "Matrix Metalloproteases: Underutilized Targets for Drug Delivery",
      "author" : [ "D.G. Vartak", "R.A. Gemeinhart" ],
      "venue" : "J. Drug Target",
      "citeRegEx" : "Vartak and Gemeinhart,? \\Q2007\\E",
      "shortCiteRegEx" : "Vartak and Gemeinhart",
      "year" : 2007
    }, {
      "title" : "Emerging Roles of Proteases in Tumour Suppression",
      "author" : [ "C. Lopez-Otin", "L.M. Matrisian" ],
      "venue" : "Nat. Rev. Cancer 2007,",
      "citeRegEx" : "Lopez.Otin and Matrisian,? \\Q2007\\E",
      "shortCiteRegEx" : "Lopez.Otin and Matrisian",
      "year" : 2007
    }, {
      "title" : "Theranostic Applications of Nanoparticles in Cancer",
      "author" : [ "N. Ahmed", "H. Fessi", "A. Elaissari" ],
      "venue" : "Drug Discov. Today 2012,",
      "citeRegEx" : "Ahmed et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Ahmed et al\\.",
      "year" : 2012
    }, {
      "title" : "Theranostics: Combining Imaging and Therapy",
      "author" : [ "S.S. Kelkar", "T.M. Reineke" ],
      "venue" : "Bioconjugate Chem 2011,",
      "citeRegEx" : "Kelkar and Reineke,? \\Q1903\\E",
      "shortCiteRegEx" : "Kelkar and Reineke",
      "year" : 1903
    }, {
      "title" : "Dendrimer-Based Nanoparticles for Cancer Therapy",
      "author" : [ "J.R. Baker" ],
      "venue" : "Hematology 2009,",
      "citeRegEx" : "Baker,? \\Q2009\\E",
      "shortCiteRegEx" : "Baker",
      "year" : 2009
    }, {
      "title" : "Targeting of Pancreatic Cancer with MagnetoFluorescent Theranostic Gold Nanoshells",
      "author" : [ "W. Chen", "C. Ayala-Orozco", "N.C. Biswal", "C. Perez-Torres", "M. Bartels", "R. Bardhan", "G. Stinnet", "X.-D. Liu", "B. Ji", "A. Deorukhkar", "L. V Brown", "S. Guha", "R.G. Pautler", "S. Krishnan", "N.J. Halas", "A. Joshi" ],
      "venue" : "Nanomedicine (Lond) 2014,",
      "citeRegEx" : "Chen et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Chen et al\\.",
      "year" : 2014
    }, {
      "title" : "Nanostructures in Biodiagnostics",
      "author" : [ "N.L. Rosi", "C.A. Mirkin" ],
      "venue" : "Chem. Rev",
      "citeRegEx" : "Rosi and Mirkin,? \\Q2005\\E",
      "shortCiteRegEx" : "Rosi and Mirkin",
      "year" : 2005
    }, {
      "title" : "Engineered Nanoparticles for Drug Delivery in Cancer Therapy",
      "author" : [ "T. Sun", "Y.S. Zhang", "B. Pang", "D.C. Hyun", "M. Yang", "Y. Xia" ],
      "venue" : "Angew. Chemie - Int. Ed. 2014,",
      "citeRegEx" : "Sun et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Sun et al\\.",
      "year" : 2014
    }, {
      "title" : "Pericellular Hydrogel/nanonets Inhibit Cancer Cells",
      "author" : [ "Y. Kuang", "J. Shi", "J. Li", "D. Yuan", "K.A. Alberti", "Q. Xu", "B. Xu" ],
      "venue" : "Angew. Chemie - Int. Ed. 2014,",
      "citeRegEx" : "Kuang et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Kuang et al\\.",
      "year" : 2014
    }, {
      "title" : "Molecular Hydrogels of Therapeutic Agents",
      "author" : [ "F. Zhao", "M. Lung Ma", "B. Xu" ],
      "venue" : "Chem. Soc. Rev. 2009,",
      "citeRegEx" : "Zhao et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Zhao et al\\.",
      "year" : 2009
    }, {
      "title" : "Incorporation of a Matrix Metalloproteinase-Sensitive Substrate into SelfAssembling Peptides - A Model for Biofunctional Scaffolds",
      "author" : [ "Y. Chau", "Y. Luo", "A.C.Y. Cheung", "Y. Nagai", "S. Zhang", "J.B. Kobler", "S.M. Zeitels", "R. Langer" ],
      "venue" : "Biomaterials",
      "citeRegEx" : "Chau et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Chau et al\\.",
      "year" : 2008
    }, {
      "title" : "Antibody-Drug Conjugates for Cancer Therapy",
      "author" : [ "P.J. Carter", "P.D. Senter" ],
      "venue" : "Cancer J. 2008,",
      "citeRegEx" : "Carter and Senter,? \\Q2008\\E",
      "shortCiteRegEx" : "Carter and Senter",
      "year" : 2008
    }, {
      "title" : "Self-Assembled Lipid-Polymer Hybrid Nanoparticles: A Robust Drug Delivery Platform",
      "author" : [ "L. Zhang", "J.M. Chan", "F.X. Gu", "J.W. Rhee", "A.Z. Wang", "A.F. Radovic-Moreno", "F. Alexis", "R. Langer", "O.C. Farokhzad" ],
      "venue" : "ACS Nano 2008,",
      "citeRegEx" : "Zhang et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Zhang et al\\.",
      "year" : 2008
    }, {
      "title" : "Formulation of Functionalized PLGA-PEG Nanoparticles for in Vivo Targeted Drug Delivery",
      "author" : [ "J. Cheng", "B.A. Teply", "I. Sherifi", "J. Sung", "G. Luther", "F.X. Gu", "E. Levy-Nissenbaum", "A.F. Radovic-Moreno", "R. Langer", "O.C. Farokhzad" ],
      "venue" : "Biomaterials",
      "citeRegEx" : "Cheng et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Cheng et al\\.",
      "year" : 2007
    }, {
      "title" : "Nanocarriers as an Emerging Platform for Cancer Therapy",
      "author" : [ "D. Peer", "J.M. Karp", "S. Hong", "O.C. Farokhzad", "R. Margalit", "R. Langer" ],
      "venue" : "Nat. Nanotechnol",
      "citeRegEx" : "Peer et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Peer et al\\.",
      "year" : 2007
    }, {
      "title" : "Design Considerations for Tumour-Targeted Nanoparticles",
      "author" : [ "H.S. Choi", "W. Liu", "F. Liu", "K. Nasr", "P. Misra", "M.G. Bawendi", "J.V. Frangioni" ],
      "venue" : "Nat. Nanotechnol",
      "citeRegEx" : "Choi et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Choi et al\\.",
      "year" : 2010
    }, {
      "title" : "Multifunctional Nanoparticles for Multimodal Imaging and Theragnosis",
      "author" : [ "D.-E. Lee", "H. Koo", "I.-C. Sun", "J. Hee Ryu", "K. Kim", "I. Chan Kwon" ],
      "venue" : "Chem. Soc. Rev",
      "citeRegEx" : "Lee et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Lee et al\\.",
      "year" : 2012
    }, {
      "title" : "Shape Effects of Filaments versus Spherical Particles in Flow and Drug Delivery",
      "author" : [ "Y. Geng", "P. Dalhaimer", "S. Cai", "R. Tsai", "M. Tewari", "T. Minko", "D.E. Discher" ],
      "venue" : "Nat. Nanotechnol",
      "citeRegEx" : "Geng et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Geng et al\\.",
      "year" : 2007
    }, {
      "title" : "Building Nanostructures with Drugs",
      "author" : [ "W. Ma", "A.G. Cheetham", "H. Cui" ],
      "venue" : "Nano Today 2015,",
      "citeRegEx" : "Ma et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Ma et al\\.",
      "year" : 2015
    }, {
      "title" : "Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy",
      "author" : [ "M.K. Yu", "J. Park", "S. Jon", "J. Sangyong" ],
      "venue" : "Theranostics 2012,",
      "citeRegEx" : "Yu et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Yu et al\\.",
      "year" : 2012
    }, {
      "title" : "Imaging Enzyme-Triggered Self-Assembly of Small Molecules inside Live Cells",
      "author" : [ "Y. Gao", "J. Shi", "D. Yuan", "B. Xu" ],
      "venue" : "Nat. Commun",
      "citeRegEx" : "Gao et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Gao et al\\.",
      "year" : 2012
    }, {
      "title" : "Strategies for in Vivo Imaging of Enzyme Activity: An Overview and Recent Advances",
      "author" : [ "A. Razgulin", "N. Ma", "J. Rao" ],
      "venue" : "Chem. Soc. Rev. 2011,",
      "citeRegEx" : "Razgulin et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Razgulin et al\\.",
      "year" : 2011
    }, {
      "title" : "EnvironmentSensitive Fluorescent Supramolecular Nanofibers for Imaging Applications",
      "author" : [ "Y. Cai", "Y. Shi", "H. Wang", "J. Wang", "D. Ding", "L. Wang", "Z. Yang" ],
      "venue" : "Anal. Chem",
      "citeRegEx" : "Cai et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Cai et al\\.",
      "year" : 2014
    }, {
      "title" : "In Vivo Imaging of Proteolytic Enzyme Activity Using a Novel Molecular Reporter In Vivo Imaging of Proteolytic Enzyme Activity Using a Novel Molecular Reporter 1",
      "author" : [ "C. Tung", "U. Mahmood", "S. Bredow", "R. Weissleder" ],
      "venue" : "Cancer Res",
      "citeRegEx" : "Tung et al\\.,? \\Q2000\\E",
      "shortCiteRegEx" : "Tung et al\\.",
      "year" : 2000
    }, {
      "title" : "In Vivo Imaging of Tumors with Protease-Activated near-Infrared Fluorescent Probes",
      "author" : [ "R. Weissleder", "C.-H. Tung", "U. Mahmood", "A. Bogdanov" ],
      "venue" : "Nat. Biotechnol",
      "citeRegEx" : "Weissleder et al\\.,? \\Q1999\\E",
      "shortCiteRegEx" : "Weissleder et al\\.",
      "year" : 1999
    }, {
      "title" : "Imaging in the Era of Molecular Oncology",
      "author" : [ "R. Weissleder", "M.J. Pittet" ],
      "venue" : "Nature",
      "citeRegEx" : "Weissleder and Pittet,? \\Q2008\\E",
      "shortCiteRegEx" : "Weissleder and Pittet",
      "year" : 2008
    }, {
      "title" : "Activatable Nanoprobes for Biomolecular Detection",
      "author" : [ "P. Zhang", "A.G. Cheetham", "L.L. Lock", "Y. Li", "H. Cui" ],
      "venue" : "Curr. Opin. Biotechnol",
      "citeRegEx" : "Zhang et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Zhang et al\\.",
      "year" : 2015
    }, {
      "title" : "Design and Assembly of Supramolecular Dual-Modality Nanoprobes",
      "author" : [ "S. Liu", "P. Zhang", "S.R. Banerjee", "J. Xu", "M.G. Pomper", "H. Cui" ],
      "venue" : "Nanoscale 2015,",
      "citeRegEx" : "Liu et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 2015
    }, {
      "title" : "TumorTrageting Multi-Functional Nanoparticles for Theragnosis: New Paradigm for Cancer Therapy",
      "author" : [ "J.H. Ryu", "H. Koo", "I.-C. Sun", "S.H. Yuk", "K. Choi", "K. Kim", "I.C. Kwon" ],
      "venue" : "Adv. Drug Deliv. Rev",
      "citeRegEx" : "Ryu et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Ryu et al\\.",
      "year" : 2012
    }, {
      "title" : "Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities",
      "author" : [ "Z. Cheng", "A. Al Zaki", "J.Z. Hui", "V.R. Muzykantov", "A. Tsourkas" ],
      "venue" : "Science",
      "citeRegEx" : "Cheng et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Cheng et al\\.",
      "year" : 2012
    }, {
      "title" : "Imaging and Drug Delivery Using Theranostic Nanoparticles",
      "author" : [ "S.M. Janib", "A.S. Moses", "J.A. Mackay" ],
      "venue" : "Adv. Drug Deliv. Rev. 2010,",
      "citeRegEx" : "Janib et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Janib et al\\.",
      "year" : 2010
    }, {
      "title" : "Theranostic Nanomedicine",
      "author" : [ "T. Lammers", "S. Aime", "W.E. Hennink", "G. Storm", "F. Kiessling" ],
      "venue" : "Acc. Chem. Res. 2011,",
      "citeRegEx" : "Lammers et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Lammers et al\\.",
      "year" : 2011
    }, {
      "title" : "Image Guided Therapy: The Advent of Theranostic Agents",
      "author" : [ "E. Terreno", "F. Uggeri", "S. Aime" ],
      "venue" : "J. Control. Release",
      "citeRegEx" : "Terreno et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Terreno et al\\.",
      "year" : 2012
    }, {
      "title" : "Nanotheranostics for Personalized Medicine",
      "author" : [ "S. Mura", "P. Couvreur" ],
      "venue" : "Adv. Drug Deliv. Rev. 2012,",
      "citeRegEx" : "Mura and Couvreur,? \\Q2012\\E",
      "shortCiteRegEx" : "Mura and Couvreur",
      "year" : 2012
    }, {
      "title" : "Gel-Liposome-Mediated Co-Delivery of Anticancer Membrane-Associated Proteins and Small-Molecule Drugs for Enhanced Therapeutic Efficacy",
      "author" : [ "T. Jiang", "R. Mo", "A. Bellotti", "J. Zhou", "Z. Gu" ],
      "venue" : "Adv. Funct. Mater. 2014,",
      "citeRegEx" : "Jiang et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Jiang et al\\.",
      "year" : 2014
    }, {
      "title" : "Pharmacokinetics and Biodistribution of Nanoparticles",
      "author" : [ "S.-D. Li", "L. Huang" ],
      "venue" : "Mol. Pharm. 2008,",
      "citeRegEx" : "Li and Huang,? \\Q2008\\E",
      "shortCiteRegEx" : "Li and Huang",
      "year" : 2008
    }, {
      "title" : "Controlled Release of Free Doxorubicin from Peptide–drug Conjugates by Drug Loading",
      "author" : [ "Z. Chen", "P. Zhang", "A.G. Cheetham", "J.H. Moon", "J.W. Moxley", "Y.-A. Lin", "H. Cui" ],
      "venue" : "J. Control. Release",
      "citeRegEx" : "Chen et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Chen et al\\.",
      "year" : 2014
    }, {
      "title" : "PEG Shielded MMP Sensitive CPPs for Efficient and Tumor Specific Gene Delivery in Vivo",
      "author" : [ "K.-L. Veiman", "K. Künnapuu", "T. Lehto", "K. Kiisholts", "K. Pärn", "Ü. Langel", "K. Kurrikoff" ],
      "venue" : "J. Control. Release",
      "citeRegEx" : "Veiman et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Veiman et al\\.",
      "year" : 2015
    }, {
      "title" : "Enhanced Anticancer Activity of Nanopreparation Containing an MMP2-Sensitive PEG-Drug Conjugate and Cell-Penetrating Moiety",
      "author" : [ "L. Zhu", "T. Wang", "F. Perche", "A. Taigind", "V.P. Torchilin", "A.M. Klibanov" ],
      "venue" : null,
      "citeRegEx" : "Zhu et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Zhu et al\\.",
      "year" : 2013
    }, {
      "title" : "The Urokinasetype Plasminogen Activator System in Cancer Metastasis",
      "author" : [ "PA Andreasen", "L Kjoller", "L D.M. Christensen" ],
      "venue" : "Int. J. Cancer",
      "citeRegEx" : "Andreasen et al\\.,? \\Q1997\\E",
      "shortCiteRegEx" : "Andreasen et al\\.",
      "year" : 1997
    }, {
      "title" : "Protease-Sensitive, Polymer-Caged Liposomes: A Method for Making Highly Targeted Liposomes Using Triggered Release",
      "author" : [ "M.T. Basel", "T.B. Shrestha", "D.L. Troyer", "S.H. Bossmann" ],
      "venue" : "ACS Nano 2011,",
      "citeRegEx" : "Basel et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Basel et al\\.",
      "year" : 2011
    }, {
      "title" : "Enzyme-Induced and Tumor-Targeted Drug Delivery System Based on Multifunctional Mesoporous Silica Nanoparticles",
      "author" : [ "Y.-J. Cheng", "G.-F. Luo", "J.-Y. Zhu", "X.-D. Xu", "X. Zeng", "D.-B. Cheng", "Y.-M. Li", "Y. Wu", "X.-Z. Zhang", "R.-X. Zhuo", "F. He" ],
      "venue" : "ACS Appl. Mater. Interfaces 2015,",
      "citeRegEx" : "Cheng et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Cheng et al\\.",
      "year" : 2015
    }, {
      "title" : "MMP‐9 Responsive PEG Cleavable Nanovesicles for Efficient Delivery of Chemotherapeutics to Pancreatic Cancer",
      "author" : [ "P.S. Kulkarni", "M.K. Haldar", "R.R. Nahire", "P. Katti", "A.H. Ambre", "W.W. Muhonen", "J.B. Shabb", "∥ Sathish", "K.R. Padi", "R.K. Singh", "P.P. Borowicz", "D.K. Shrivastava", "K.S. Katti", "K. Reindl", "B. Guo", "S. Mallik" ],
      "venue" : "Mol. Pharm. 2014,",
      "citeRegEx" : "Kulkarni et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Kulkarni et al\\.",
      "year" : 2014
    }, {
      "title" : "Cancer Cell Death Induced by the Intracellular Self-Assembly of an Enzyme-Responsive Supramolecular Gelator",
      "author" : [ "A. Tanaka", "Y. Fukuoka", "Y. Morimoto", "T. Honjo", "D. Koda", "M. Goto", "T. Maruyama" ],
      "venue" : "J. Am. Chem. Soc",
      "citeRegEx" : "Tanaka et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Tanaka et al\\.",
      "year" : 2015
    }, {
      "title" : "Enzymatic Formation of Supramolecular Hydrogels",
      "author" : [ "B.Z. Yang", "H. Gu", "D. Fu", "P. Gao" ],
      "venue" : "Adv. Mater. 2004,",
      "citeRegEx" : "Yang et al\\.,? \\Q2004\\E",
      "shortCiteRegEx" : "Yang et al\\.",
      "year" : 2004
    }, {
      "title" : "Enzyme-Instructed Molecular Self-Assembly Confers Nanofibers and a Supramolecular Hydrogel of Taxol Derivative",
      "author" : [ "Y. Gao", "Y. Kuang", "Z.-F. Guo", "Z. Guo", "I.J. Krauss", "B. Xu" ],
      "venue" : "J. Am. Chem. Soc",
      "citeRegEx" : "Gao et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Gao et al\\.",
      "year" : 2009
    }, {
      "title" : "Enzyme-Instructed Self-Assembly of Small D‐Peptides as a Multiple- Step Process for Selectively Killing Cancer Cells",
      "author" : [ "J. Zhou", "X. Du", "N. Yamagata", "B. Xu" ],
      "venue" : "J. Am. Chem. Soc. 2016,",
      "citeRegEx" : "Zhou et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Zhou et al\\.",
      "year" : 2016
    }, {
      "title" : "Integrating Enzymatic SelfAssembly and Mitochondria Targeting for Selectively Killing Cancer Cells without Acquired Drug Resistance",
      "author" : [ "H. Wang", "Z. Feng", "Y. Wang", "R. Zhou", "Z. Yang", "B. Xu" ],
      "venue" : "J. Am. Chem. Soc. 2016,",
      "citeRegEx" : "Wang et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2016
    }, {
      "title" : "MMP-9 Triggered Micelle-to-Fibre Transitions for Slow Release of Doxorubicin",
      "author" : [ "D. Kalafatovic", "M. Nobis", "N. Javid", "P.W.J.M. Frederix", "K.I. Anderson", "B.R. Saunders", "R.V. Ulijn" ],
      "venue" : "Biomater. Sci",
      "citeRegEx" : "Kalafatovic et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Kalafatovic et al\\.",
      "year" : 2015
    }, {
      "title" : "MMP-9 Triggered SelfAssembly of Doxorubicin Nanofiber Depots Halts Tumor Growth",
      "author" : [ "D. Kalafatovic", "M. Nobis", "J. Son", "K.I. Anderson", "R.V. Ulijn" ],
      "venue" : "Biomaterials 2016,",
      "citeRegEx" : "Kalafatovic et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Kalafatovic et al\\.",
      "year" : 2016
    }, {
      "title" : "Preparation of a Cathepsin D Sensitive Near-Infrared Fluorescence Probe for Imaging",
      "author" : [ "C.-H. Tung", "S. Bredow", "U. Mahmood", "R. Weissleder" ],
      "venue" : "Bioconjugate Chem. 1999,",
      "citeRegEx" : "Tung et al\\.,? \\Q1999\\E",
      "shortCiteRegEx" : "Tung et al\\.",
      "year" : 1999
    }, {
      "title" : "Proteolytic Activity Monitored by Fluorescence Resonance Energy Transfer through Quantum-Dot–peptide Conjugates",
      "author" : [ "I.L. Medintz", "A.R. Clapp", "F.M. Brunel", "T. Tiefenbrunn", "H. Tetsuo Uyeda", "E.L. Chang", "J.R. Deschamps", "P.E. Dawson", "H. Mattoussi" ],
      "venue" : "Nat. Mater. 2006,",
      "citeRegEx" : "Medintz et al\\.,? \\Q2006\\E",
      "shortCiteRegEx" : "Medintz et al\\.",
      "year" : 2006
    }, {
      "title" : "Topical MMP Beacon Enabled Fluorescence- Guided Resection of Oral Carcinoma",
      "author" : [ "P. Lane", "C. Macaulay" ],
      "venue" : "Opt. Soc. Am. 2016,",
      "citeRegEx" : "M. et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "M. et al\\.",
      "year" : 2016
    }, {
      "title" : "Intraoperative Imaging-Guided Cancer Surgery: From Current Fluorescence Molecular Imaging Methods to Future Multi-Modality Imaging Technology",
      "author" : [ "C. Chi", "Y. Du", "J. Ye", "D. Kou", "J. Qiu", "J. Wang", "J. Tian", "X. Chen" ],
      "venue" : "Theranostics 2014,",
      "citeRegEx" : "Chi et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Chi et al\\.",
      "year" : 2014
    }, {
      "title" : "Cell-Permeable and Biocompatible Polymeric Nanoparticles for Apoptosis Imaging",
      "author" : [ "K. Kim", "M. Lee", "H. Park", "J.-H. Kim", "S. Kim", "H. Chung", "K. Choi", "I.-S. Kim", "B.L. Seong", "I.C. Kwon" ],
      "venue" : "J. Am. Chem. Soc",
      "citeRegEx" : "Kim et al\\.,? \\Q2006\\E",
      "shortCiteRegEx" : "Kim et al\\.",
      "year" : 2006
    }, {
      "title" : "A Near-Infrared-Fluorescence-Quenched GoldNanoparticle Imaging Probe for In Vivo Drug Screening and Protease Activity Determination",
      "author" : [ "S. Lee", "E.-J. Cha", "K. Park", "S.-Y. Lee", "J.-K. Hong", "I.-C. Sun", "S.Y. Kim", "K. Choi", "I.C. Kwon", "K. Kim", "C.-H. Ahn" ],
      "venue" : "Angew. Chemie Int. Ed",
      "citeRegEx" : "Lee et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Lee et al\\.",
      "year" : 2008
    }, {
      "title" : "Specific Detection and Imaging of Enzyme Activity by Signal-Amplifiable Self-Assembling (19)F MRI Probes",
      "author" : [ "K. Matsuo", "R. Kamada", "K. Mizusawa", "H. Imai", "Y. Takayama", "M. Narazaki", "T. Matsuda", "Y. Takaoka", "I. Hamachi" ],
      "venue" : "Chemistry (Easton)",
      "citeRegEx" : "Matsuo et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Matsuo et al\\.",
      "year" : 2013
    }, {
      "title" : "Visualization of Protease Activity In Vivo Using an Activatable Photo-Acoustic Imaging Probe Based on CuS Nanoparticles",
      "author" : [ "K. Yang", "L. Zhu", "L. Nie", "X. Sun", "L. Cheng", "C. Wu", "G. Niu", "X. Chen", "Z. Liu" ],
      "venue" : "Theranostics 2014,",
      "citeRegEx" : "Yang et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Yang et al\\.",
      "year" : 2014
    }, {
      "title" : "Tumor Imaging by Means of Proteolytic Activation of Cell-Penetrating Peptides",
      "author" : [ "T. Jiang", "E.S. Olson", "Q.T. Nguyen", "M. Roy", "P.A. Jennings", "R.Y. Tsien" ],
      "venue" : null,
      "citeRegEx" : "Jiang et al\\.,? \\Q2004\\E",
      "shortCiteRegEx" : "Jiang et al\\.",
      "year" : 2004
    }, {
      "title" : "Overcoming Multidrug Resistance of Small-Molecule Therapeutics through Conjugation with Releasable Octaarginine Transporters",
      "author" : [ "E.A. Dubikovskaya", "S.H. Thorne", "T.H. Pillow", "C.H. Contag", "P.A. Wender" ],
      "venue" : null,
      "citeRegEx" : "Dubikovskaya et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Dubikovskaya et al\\.",
      "year" : 2008
    }, {
      "title" : "Nanomedicine for Targeted Cancer Therapy: Towards the Overcoming of Drug Resistance",
      "author" : [ "A. Shapira", "Y.D. Livney", "H.J. Broxterman", "Y.G. Assaraf" ],
      "venue" : "Drug Resist. Updat. 2011,",
      "citeRegEx" : "Shapira et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Shapira et al\\.",
      "year" : 2011
    }, {
      "title" : "In Vivo Characterization of Activatable Cell Penetrating Peptides for Targeting Protease Activity in Cancer",
      "author" : [ "E.S. Olson", "ae A. Todd Aguilera", "A. Tao Jiang", "af G. Lesley Ellies", "Q.T. Nguyen", "E.H. Wong", "L.A. Gross af", "R.Y. Tsien" ],
      "venue" : null,
      "citeRegEx" : "Olson et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Olson et al\\.",
      "year" : 2009
    }, {
      "title" : "Activatable Cell Penetrating Peptides Linked to Nanoparticles as Dual Probes for in Vivo Fluorescence and MR Imaging of Proteases",
      "author" : [ "E.S. Olson", "T. Jiang", "T.A. Aguilera", "Q.T. Nguyen", "L.G. Ellies", "M. Scadeng", "R.Y. Tsien" ],
      "venue" : null,
      "citeRegEx" : "Olson et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Olson et al\\.",
      "year" : 2010
    }, {
      "title" : "Ratiometric Activatable Cell-Penetrating Peptides Provide Rapid in Vivo Readout of Thrombin Activation",
      "author" : [ "M. Whitney", "E.N. Savariar", "B. Friedman", "R.A. Levin", "J.L. Crisp", "H.L. Glasgow", "R. Lefkowitz", "S.R. Adams", "P. Steinbach", "N. Nashi", "Q.T. Nguyen", "R.Y. Tsien" ],
      "venue" : "Angew. Chemie - Int. Ed. 2013,",
      "citeRegEx" : "Whitney et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Whitney et al\\.",
      "year" : 2013
    }, {
      "title" : "Identification of High-Risk Plaques by MRI and Fluorescence Imaging in a Rabbit Model of Atherothrombosis",
      "author" : [ "Q.T. Nguyen", "R.Y. Tsien", "J.A. Hamilton" ],
      "venue" : "PLoS One 2015,",
      "citeRegEx" : "Nguyen et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Nguyen et al\\.",
      "year" : 2015
    }, {
      "title" : "Dual Targeting of Integrin a v B 3 and Matrix Metalloproteinase- 2 for Optical Imaging of Tumors and Chemotherapeutic Delivery",
      "author" : [ "J.L. Crisp", "E.N. Savariar", "H.L. Glasgow", "L.G. Ellies", "M.A. Whitney", "R.Y. Tsien" ],
      "venue" : "Mol. Cancer Ther",
      "citeRegEx" : "Crisp et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Crisp et al\\.",
      "year" : 2014
    }, {
      "title" : "Dynamic Imaging of Protease Activity with Fluorescently Quenched ActivityBased Probes",
      "author" : [ "G. Blum", "S.R. Mullins", "K. Keren", "M. Fonovič", "C. Jedeszko", "M.J. Rice", "B.F. Sloane", "M. Bogyo" ],
      "venue" : "Nat. Chem. Biol",
      "citeRegEx" : "Blum et al\\.,? \\Q2005\\E",
      "shortCiteRegEx" : "Blum et al\\.",
      "year" : 2005
    }, {
      "title" : "Design and Construction of Supramolecular Nanobeacons for Enzyme Detection",
      "author" : [ "L.L. Lock", "A.G. Cheetham", "P. Zhang", "H. Cui" ],
      "venue" : "ACS Nano 2013,",
      "citeRegEx" : "Lock et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Lock et al\\.",
      "year" : 2013
    }, {
      "title" : "Tuning Cellular Uptake of Molecular Probes by Rational Design of Their Assembly into Supramolecular Nanoprobes",
      "author" : [ "L.L. Lock", "C.D. Reyes", "P. Zhang", "H. Cui" ],
      "venue" : "J. Am. Chem. Soc. 2016,",
      "citeRegEx" : "Lock et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Lock et al\\.",
      "year" : 2016
    }, {
      "title" : "Receptor-Targeted Nanoparticles for In Vivo Imaging of Breast Cancer",
      "author" : [ "L. Yang", "X.-H. Peng", "Y.A. Wang", "X. Wang", "Z. Cao", "C. Ni", "P. Karna", "X. Zhang", "W.C. Wood", "X. Gao", "S. Nie", "H. Mao" ],
      "venue" : "Clin. Cancer Res",
      "citeRegEx" : "Yang et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Yang et al\\.",
      "year" : 2009
    }, {
      "title" : "Protease-Sensitive Fluorescent Nanofibers",
      "author" : [ "B. Law", "R. Weissleder", "C.-H. Tung" ],
      "venue" : "Bioconjug. Chem. 2007,",
      "citeRegEx" : "Law et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Law et al\\.",
      "year" : 2007
    }, {
      "title" : "Design and Synthesis of a near-Infrared Fluorescent Nanofiber Precursor for Detecting Cell-Secreted Urokinase Activity",
      "author" : [ "R. Malik", "S. Qian", "B. Law" ],
      "venue" : "Anal. Biochem",
      "citeRegEx" : "Malik et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Malik et al\\.",
      "year" : 2011
    }, {
      "title" : "Multiplex Sensing of Protease and Kinase Enzyme Activity via Orthogonal Coupling of Quantum Dot-Peptide Conjugates",
      "author" : [ "S.B. Lowe", "J.A.G. Dick", "B.E. Cohen", "M.M. Stevens" ],
      "venue" : "ACS Nano 2012,",
      "citeRegEx" : "Lowe et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Lowe et al\\.",
      "year" : 2012
    }, {
      "title" : "Bioorthogonal Cyclization-Mediated in Situ Self-Assembly of Small-Molecule Probes for Imaging Caspase Activity in Vivo",
      "author" : [ "D. Ye", "A.J. Shuhendler", "L. Cui", "L. Tong", "S.S. Tee", "G. Tikhomirov", "D.W. Felsher", "J. Rao" ],
      "venue" : "Nat. Chem. 2014,",
      "citeRegEx" : "Ye et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Ye et al\\.",
      "year" : 2014
    }, {
      "title" : "Caspase-Responsive Smart Gadolinium-Based Contrast Agent for Magnetic Resonance Imaging of Drug-Induced Apoptosis",
      "author" : [ "D. Ye", "A.J. Shuhendler", "P. Pandit", "K.D. Brewer", "S.S. Tee", "L. Cui", "G. Tikhomirov", "B. Rutt", "J. Rao" ],
      "venue" : "Chem. Sci. 2014,",
      "citeRegEx" : "Ye et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Ye et al\\.",
      "year" : 2014
    }, {
      "title" : "A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment",
      "author" : [ "T.H. Witney", "A. Hoehne", "R.E. Reeves", "O. Ilovich", "M. Namavari", "B. Shen", "F.T. Chin", "J. Rao", "S.S. Gambhir" ],
      "venue" : "Clin. Cancer Res. 2015,",
      "citeRegEx" : "Witney et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Witney et al\\.",
      "year" : 2015
    }, {
      "title" : "Magnetic Resonance Imaging of Stem Cell Apoptosis in Arthritic Joints with a Caspase Activatable Contrast Agent",
      "author" : [ "H. Nejadnik", "D. Ye", "O.D. Lenkov", "J.S. Donig", "J.E. Martin", "R. Castillo", "N. Derugin", "B. Sennino", "J. Rao", "H. Daldrup-Link" ],
      "venue" : "ACS Nano 2015,",
      "citeRegEx" : "Nejadnik et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Nejadnik et al\\.",
      "year" : 2015
    }, {
      "title" : "Chemotherapeutic Drug Delivery to Cancer Cells Using a Combination of Folate Targeting and Tumor Microenvironment-Sensitive Polypeptides",
      "author" : [ "W. Gao", "B. Xiang", "T. Meng", "F. Liu", "X. Qi" ],
      "venue" : "Biomaterials 2013,",
      "citeRegEx" : "Gao et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Gao et al\\.",
      "year" : 2013
    }, {
      "title" : "Enzyme Sensitive, Surface Engineered Nanoparticles for Enhanced Delivery of Camptothecin",
      "author" : [ "H. Yu", "J. Chen", "S. Liu", "Q. Lu", "J. He", "Z. Zhou", "Y. Hu" ],
      "venue" : "J. Control. Release",
      "citeRegEx" : "Yu et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Yu et al\\.",
      "year" : 2015
    }, {
      "title" : "Matrix Metalloproteinase-Sensitive Size-Shrinkable Nanoparticles for Deep Tumor Penetration and pH Triggered Doxorubicin Release",
      "author" : [ "S. Ruan", "X. Cao", "X. Cun", "G. Hu", "Y. Zhou", "Y. Zhang", "L. Lu", "Q. He", "H. Gao" ],
      "venue" : "Biomaterials 2015,",
      "citeRegEx" : "Ruan et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Ruan et al\\.",
      "year" : 2015
    }, {
      "title" : "A Smart Polymeric Platform for Multistage Nucleus-Targeted Anticancer Drug Delivery",
      "author" : [ "J. Zhong", "L. Li", "X. Zhu", "S. Guan", "Q. Yang", "Z. Zhou", "Z. Zhang", "Y. Huang" ],
      "venue" : "Biomaterials 2015,",
      "citeRegEx" : "Zhong et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Zhong et al\\.",
      "year" : 2015
    }, {
      "title" : "Controlling and Switching the Morphology of Micellar Nanoparticles with Enzymes",
      "author" : [ "T.-H. Ku", "M.-P. Chien", "M.P. Thompson", "R.S. Sinkovits", "N.H. Olson", "T.S. Baker", "N.C. Gianneschi" ],
      "venue" : "J. Am. Chem. Soc 2011,",
      "citeRegEx" : "Ku et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Ku et al\\.",
      "year" : 2011
    }, {
      "title" : "Photodynamic Therapy Agent with a Built-In Apoptosis Sensor for Evaluating Its Own Therapeutic Outcome in Situ",
      "author" : [ "K. Stefflova", "J. Chen", "D. Marotta", "H. Li", "G. Zheng" ],
      "venue" : "J. Med. Chem",
      "citeRegEx" : "Stefflova et al\\.,? \\Q2006\\E",
      "shortCiteRegEx" : "Stefflova et al\\.",
      "year" : 2006
    }, {
      "title" : "Targeted Photodynamic Therapy Agent with a Built-In Apoptosis Sensor for In Vivo Near-Infrared Imaging of Tumor Apoptosis Triggered by Its Photosensitization",
      "author" : [ "K. Stefflova", "J. Chen", "H. Li", "G. Zheng" ],
      "venue" : "In Situ. Mol. Imaging 2006,",
      "citeRegEx" : "Stefflova et al\\.,? \\Q2006\\E",
      "shortCiteRegEx" : "Stefflova et al\\.",
      "year" : 2006
    }, {
      "title" : "Photodynamic Molecular Beacon as an Activatable Photosensitizer Based on Protease-Controlled Singlet Oxygen Quenching and Activation",
      "author" : [ "G. Zheng", "J. Chen", "K. Stefflova", "M. Jarvi", "H. Li", "B.C. Wilson" ],
      "venue" : null,
      "citeRegEx" : "Zheng et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Zheng et al\\.",
      "year" : 2007
    }, {
      "title" : "Imaging of Specific Activation of Photodynamic Molecular Beacons in Breast Cancer Vertebral Metastases",
      "author" : [ "T.W. Liu", "M.K. Akens", "J. Chen", "L. Wise-Milestone", "B.C. Wilson", "G. Zheng" ],
      "venue" : "Bioconjugate Chem 2011,",
      "citeRegEx" : "Liu et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 2011
    }, {
      "title" : "Matrix MetalloproteinaseBased Photodynamic Molecular Beacons for Targeted Destruction of Bone Metastases in Vivo",
      "author" : [ "T.W. Liu", "M.K. Akens", "J. Chen", "B.C. Wilson", "G. Zheng" ],
      "venue" : "Photochem. Photobiol. Sci. 2016,",
      "citeRegEx" : "Liu et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 2016
    }, {
      "title" : "Matrix Metalloproteinase Sensitive Gold Nanorod for Simultaneous Bioimaging and Photothermal Therapy of Cancer",
      "author" : [ "D.K. Yi", "I. Sun", "J.H. Ryu", "H. Koo", "C.W. Park", "I. Youn", "K. Choi", "I.C. Kwon", "K. Kim", "C. Ahn" ],
      "venue" : null,
      "citeRegEx" : "Yi et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Yi et al\\.",
      "year" : 2010
    }, {
      "title" : "Enzyme-Responsive Multifunctional Magnetic Nanoparticles for Tumor Intracellular Drug Delivery and Imaging",
      "author" : [ "Y. Yang", "J. Aw", "K. Chen", "F. Liu", "P. Padmanabhan", "Y. Hou", "Z. Cheng", "B. Xing" ],
      "venue" : "Chem. - An Asian J. 2011,",
      "citeRegEx" : "Yang et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Yang et al\\.",
      "year" : 2011
    }, {
      "title" : "Enzyme-Specific Doxorubicin Drug Beacon as Drug-Resistant Theranostic Molecular Probes",
      "author" : [ "L.L. Lock", "Z. Tang", "D. Keith", "C. Reyes", "H. Cui" ],
      "venue" : "ACS Macro Lett. 2015,",
      "citeRegEx" : "Lock et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Lock et al\\.",
      "year" : 2015
    }, {
      "title" : "Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy",
      "author" : [ "C. Ansari", "G.A. Tikhomirov", "S.H. Hong", "R.A. Falconer", "P.M. Loadman", "J.H. Gill", "R. Castaneda", "F.K. Hazard", "L. Tong", "O.D. Lenkov", "D.W. Felsher", "J. Rao", "H.E. DaldrupLink" ],
      "venue" : "Small 2014,",
      "citeRegEx" : "Ansari et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Ansari et al\\.",
      "year" : 2014
    }, {
      "title" : "Theranostic Nanoparticles with Controlled Release of Gemcitabine for Targeted Therapy and MRI of Pancreatic Cancer",
      "author" : [ "G.Y. Lee", "W.P. Qian", "L. Wang", "Y.A. Wang", "C. a Staley", "M. Satpathy", "S. Nie", "H. Mao", "L. Yang" ],
      "venue" : "ACS Nano 2013,",
      "citeRegEx" : "Lee et al\\.,? \\Q2089\\E",
      "shortCiteRegEx" : "Lee et al\\.",
      "year" : 2089
    }, {
      "title" : "Anderson received his bachelor’s degree in Chemical and Biomolecular Engineering from the Georgia Institute of Technology in 2016. He is currently a Ph,D. student in Dr. Honggang Cui’s laboratory in the department of Chemical and Biomolecular Engineering at the Johns Hopkins University. His research interests include theranostics, peptide-based",
      "author" : [ "F. Caleb" ],
      "venue" : null,
      "citeRegEx" : "Caleb,? \\Q2016\\E",
      "shortCiteRegEx" : "Caleb",
      "year" : 2016
    } ],
    "referenceMentions" : [ ],
    "year" : 2017,
    "abstractText" : "Many diseases can be characterized by the abnormal activity exhibited by various biomolecules, the targeting of which can provide therapeutic and diagnostic utility. Recent trends in medicine and nanotechnology have prompted the development of protease-sensitive nanomaterials systems for therapeutic, diagnostic, and theranostic applications. These systems can act specifically in response to the target enzyme and its associated disease conditions, thus enabling personalized treatment and improved prognosis. In this review, we discuss recent advancements in the development of protease-responsive materials for imaging and drug delivery and analyze several representative systems to illustrate their key design principles. Page 1 of 45 ACS Paragon Plus Environment Industrial & Engineering Chemistry Research 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60",
    "creator" : null
  }
}